

var createStore = Framework7.createStore;
window.store = createStore({
  state: {
    drugs: [
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210574",
        "drugId": 210574,
        "drugPrimaryName": "CBP-7005",
        "drugNameSynonyms": ["CBP 7005", "CBP-7005", "CBP7005"],
        "overview": "CBP-7005 is a mRNA therapy under development by Coherent Biopharma for an undisclosed indication (Company pipeline, Coherent Biopharma, 16 Feb 2022, https://www.coherentbio.com/#/Pipeline).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is in preclinical studies (Company pipeline, Coherent Biopharma, 16 Feb 2022, https://www.coherentbio.com/#/Pipeline).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Coherent Biopharma",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "12836",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 20,
            "name": "NA/Unspecified",
            "indications": [
              {
                "diseaseName": "Undisclosed",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [],
                "drugIcd9": [],
                "drugIcd10": [],
                "drugSnomed": []
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-16T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-16T17:06:38.143Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Messenger RNA",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Unidentified pharmacological activity",
            "mechanismSynonyms": [],
            "mechanismHierarchy": "Unidentified pharmacological activity"
          }],
        "deliveryRoutes": ["Unspecified"],
        "drugSupportingUrls": ["https://www.coherentbio.com/#/Pipeline"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Biological, nucleic acid",
        "casNumbers": [],
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "China",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "China",
        "updatedDate": "2022-02-16T17:10:50.923Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210575",
        "drugId": 210575,
        "drugPrimaryName": "CBP-7015",
        "drugNameSynonyms": ["CBP 7015", "CBP-7015", "CBP7015"],
        "overview": "CBP-7015 is a mRNA therapy under development by Coherent Biopharma for an undisclosed indication (Company pipeline, Coherent Biopharma, 16 Feb 2022, https://www.coherentbio.com/#/Pipeline).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is in preclinical studies (Company pipeline, Coherent Biopharma, 16 Feb 2022, https://www.coherentbio.com/#/Pipeline).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Coherent Biopharma",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "12836",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 20,
            "name": "NA/Unspecified",
            "indications": [
              {
                "diseaseName": "Undisclosed",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [],
                "drugIcd9": [],
                "drugIcd10": [],
                "drugSnomed": []
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-16T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-16T17:39:27.93Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Messenger RNA",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Unidentified pharmacological activity",
            "mechanismSynonyms": [],
            "mechanismHierarchy": "Unidentified pharmacological activity"
          }],
        "deliveryRoutes": ["Unspecified"],
        "drugSupportingUrls": ["https://www.coherentbio.com/#/Pipeline"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Biological, nucleic acid",
        "casNumbers": [],
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "China",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "China",
        "updatedDate": "2022-02-16T17:42:50.91Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210577",
        "drugId": 210577,
        "drugPrimaryName": "CBP-7106",
        "drugNameSynonyms": ["CBP 7106", "CBP-7106", "CBP7106"],
        "overview": "CBP-7106 is a siRNA therapy, under development by Coherent Biopharma for an undisclosed indication (Company pipeline, Coherent Biopharma, 16 Feb 2022, https://www.coherentbio.com/#/Pipeline).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is in preclinical studies (Company pipeline, Coherent Biopharma, 16 Feb 2022, https://www.coherentbio.com/#/Pipeline).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Coherent Biopharma",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "12836",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 20,
            "name": "NA/Unspecified",
            "indications": [
              {
                "diseaseName": "Undisclosed",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [],
                "drugIcd9": [],
                "drugIcd10": [],
                "drugSnomed": []
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-16T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-16T17:59:43.263Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "RNA interference",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Gene expression inhibitor",
            "mechanismSynonyms": ["Gene promoter inhibitor", "General transcription inhibitor", "General translation inhibitor"],
            "mechanismHierarchy": "Gene expression inhibitor"
          }],
        "deliveryRoutes": ["Unspecified"],
        "drugSupportingUrls": ["https://www.coherentbio.com/#/Pipeline"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Chemical, synthetic, nucleic acid",
        "casNumbers": [],
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "China",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "China",
        "updatedDate": "2022-02-16T18:07:22.957Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210578",
        "drugId": 210578,
        "drugPrimaryName": "CBP-1203",
        "drugNameSynonyms": ["CBP 1203", "CBP-1203", "CBP1203"],
        "overview": "CBP-1203 is a radio-ligand drug conjugate, under development by Coherent Biopharma for the treatment of an undisclosed indication (Company pipeline, Coherent Biopharma, 16 Feb 2022, https://www.coherentbio.com/#/Pipeline).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is in preclinical development (Company pipeline, Coherent Biopharma, 16 Feb 2022, https://www.coherentbio.com/#/Pipeline).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Coherent Biopharma",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "12836",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 20,
            "name": "NA/Unspecified",
            "indications": [
              {
                "diseaseName": "Undisclosed",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [],
                "drugIcd9": [],
                "drugIcd10": [],
                "drugSnomed": []
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-16T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-16T18:32:25.94Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Undisclosed",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Radiopharmaceutical",
            "mechanismSynonyms": ["Radiocompound", "Medicinal radiocompound"],
            "mechanismHierarchy": "Radiopharmaceutical"
          }],
        "deliveryRoutes": ["Unspecified"],
        "drugSupportingUrls": ["https://www.coherentbio.com/#/Pipeline"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Chemical, synthetic",
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "China",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "China",
        "updatedDate": "2022-02-17T17:38:38.48Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210579",
        "drugId": 210579,
        "drugPrimaryName": "CBP-9009",
        "drugNameSynonyms": ["CBP 9009", "CBP-9009", "CBP9009"],
        "overview": "CBP-9009 is a chimaeric antigen receptor T-cell (CAR-T) therapy, under development by Coherent Biopharma for an undisclosed indication (Company pipeline, Coherent Biopharma, 16 Feb 2022, https://www.coherentbio.com/#/Pipeline).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is in preclinical studies (Company pipeline, Coherent Biopharma, 16 Feb 2022, https://www.coherentbio.com/#/Pipeline).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Coherent Biopharma",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "12836",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 20,
            "name": "NA/Unspecified",
            "indications": [
              {
                "diseaseName": "Undisclosed",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [],
                "drugIcd9": [],
                "drugIcd10": [],
                "drugSnomed": []
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-16T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-16T18:34:00.037Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Gene therapy",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Cellular therapy, chimaeric antigen receptor",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "T cell stimulant",
            "mechanismSynonyms": ["General T cells stimulant", "T cells general stimulant"],
            "mechanismHierarchy": "Lymphocyte stimulant:T cell stimulant"
          }],
        "deliveryRoutes": ["Injectable", "Injectable, intravenous"],
        "drugSupportingUrls": ["https://www.coherentbio.com/#/Pipeline"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Biological, cellular",
        "casNumbers": [],
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "China",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "China",
        "updatedDate": "2022-02-16T19:05:54.453Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210580",
        "drugId": 210580,
        "drugPrimaryName": "antibody-drug conjugates, Coherent Biopharma",
        "drugNameSynonyms": ["antibody-drug conjugates, Coherent Biopharma"],
        "overview": "Coherent Biopharma is developing antibody-drug conjugates for the treatment of undisclosed indications (Company pipeline, Coherent Biopharma, 16 Feb 2022, https://www.coherentbio.com/#/Pipeline).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "They are in preclinical development (Company pipeline, Coherent Biopharma, 16 Feb 2022, https://www.coherentbio.com/#/Pipeline).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Coherent Biopharma",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "12836",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 20,
            "name": "NA/Unspecified",
            "indications": [
              {
                "diseaseName": "Undisclosed",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [],
                "drugIcd9": [],
                "drugIcd10": [],
                "drugSnomed": []
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-16T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-16T18:46:13.637Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Antibody-drug conjugate",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Unidentified pharmacological activity",
            "mechanismSynonyms": [],
            "mechanismHierarchy": "Unidentified pharmacological activity"
          }],
        "deliveryRoutes": ["Unspecified"],
        "drugSupportingUrls": ["https://www.coherentbio.com/#/Pipeline"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Chemical, synthetic",
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "China",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "China",
        "updatedDate": "2022-02-17T17:58:29.313Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210581",
        "drugId": 210581,
        "drugPrimaryName": "chimaeric antigen receptor natural killer cell therapy, Coherent Biopharma",
        "drugNameSynonyms": ["CAR-NK cells, Coherent Biopharma", "CAR-NK therapy, Coherent Biopharma", "chimaeric antigen receptor natural killer cell therapy, Coherent Biopharma"],
        "overview": "Coherent Biopharma is developing a chimaeric antigen receptor (CAR) NK therapy, for an undisclosed indication (Company pipeline, Coherent Biopharma, 16 Feb 2022, https://www.coherentbio.com/#/Pipeline).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is in preclinical studies (Company pipeline, Coherent Biopharma, 16 Feb 2022, https://www.coherentbio.com/#/Pipeline).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Coherent Biopharma",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "12836",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 20,
            "name": "NA/Unspecified",
            "indications": [
              {
                "diseaseName": "Undisclosed",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [],
                "drugIcd9": [],
                "drugIcd10": [],
                "drugSnomed": []
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-16T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-16T19:23:22.32Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Gene therapy",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Cellular therapy, chimaeric antigen receptor",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Natural killer cell stimulant",
            "mechanismSynonyms": ["NK cell stimulant"],
            "mechanismHierarchy": "Lymphocyte stimulant:Natural killer cell stimulant"
          }],
        "deliveryRoutes": ["Injectable", "Injectable, intravenous"],
        "drugSupportingUrls": ["https://www.coherentbio.com/#/Pipeline"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Biological, cellular",
        "casNumbers": [],
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "China",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "China",
        "updatedDate": "2022-02-16T19:26:01.757Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210582",
        "drugId": 210582,
        "drugPrimaryName": "300mg MYMD-1",
        "drugNameSynonyms": ["300mg MYMD-1"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-16T23:33:50.11Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210583",
        "drugId": 210583,
        "drugPrimaryName": "600mg MYMD-1",
        "drugNameSynonyms": ["600mg MYMD-1"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-16T23:34:35.877Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210584",
        "drugId": 210584,
        "drugPrimaryName": "AC176",
        "drugNameSynonyms": ["AC176", "AC176_dupe"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-18T15:47:26.393Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210585",
        "drugId": 210585,
        "drugPrimaryName": "Ad26/protein preF RSV Vaccine",
        "drugNameSynonyms": ["Ad26/protein preF RSV Vaccine"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-16T23:34:49.367Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210586",
        "drugId": 210586,
        "drugPrimaryName": "CAR-BCMA",
        "drugNameSynonyms": ["CAR-BCMA"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-16T23:34:56.29Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210587",
        "drugId": 210587,
        "drugPrimaryName": "CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine",
        "drugNameSynonyms": ["CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425234],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-16T23:35:03.48Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210588",
        "drugId": 210588,
        "drugPrimaryName": "Fosaprepitant , Tropisetron and Olanzapine",
        "drugNameSynonyms": ["Fosaprepitant , Tropisetron and Olanzapine"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-16T23:35:10.41Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210589",
        "drugId": 210589,
        "drugPrimaryName": "Fosaprepitant , Tropisetron, Dexamethasoneand Olanzapine",
        "drugNameSynonyms": ["Fosaprepitant , Tropisetron, Dexamethasoneand Olanzapine"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-16T23:35:17.503Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210590",
        "drugId": 210590,
        "drugPrimaryName": "Fruquintinib + RC48",
        "drugNameSynonyms": ["Fruquintinib + RC48"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425259],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-16T23:35:25.13Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210591",
        "drugId": 210591,
        "drugPrimaryName": "Huperzine A Injection",
        "drugNameSynonyms": ["Huperzine A Injection"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425248],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-16T23:35:31.99Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210592",
        "drugId": 210592,
        "drugPrimaryName": "Interferon Beta-1A Prefilled Syringe",
        "drugNameSynonyms": ["Interferon Beta-1A Prefilled Syringe"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425251],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-16T23:35:38.823Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210593",
        "drugId": 210593,
        "drugPrimaryName": "JNJ-78934804",
        "drugNameSynonyms": ["JNJ 78934804", "JNJ-78934804", "JNJ78934804"],
        "overview": "JNJ-78934804 is under development by Johnson & Johnson for the treatment of Crohn's disease (ClinicalTrials.gov, 16 Feb 2022, https://clinicaltrials.gov/ct2/show/NCT05242471).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "Crohn's disease\nA randomized, double-blind, active-controlled, parallel-group Phase IIb trial (DUET-CD; CR109178) in Italy in 650 subjects with moderately to severely active Crohn's disease, to evaluate the efficacy and safety of induction and maintenance of JNJ-78934804 sc in combination with guselkumab and golimumab, is planned (ClinicalTrials.gov, 16 Feb 2022, https://clinicaltrials.gov/ct2/show/NCT05242471).",
        "phaseIII": "",
        "preClinical": "",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Johnson & Johnson",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "316",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 3,
            "name": "Alimentary/Metabolic Products",
            "indications": [
              {
                "diseaseName": "Crohn's disease",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D003424",
                    "name": "Crohn Disease"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:555.0-555.9",
                    "name": "Regional enteritis of large intestine"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "K50.90",
                    "name": "Crohn's disease, unspecified, without complications"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED34000006",
                    "name": "Crohn's disease"
                  }]
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-18T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-18T08:22:46.283Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "GI inflammatory/bowel disorders",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Unidentified pharmacological activity",
            "mechanismSynonyms": [],
            "mechanismHierarchy": "Unidentified pharmacological activity"
          }],
        "deliveryRoutes": ["Injectable", "Injectable, subcutaneous"],
        "drugSupportingUrls": ["https://clinicaltrials.gov/ct2/show/NCT05242471"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Chemical, synthetic",
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "USA",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [425243],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "USA",
        "updatedDate": "2022-02-18T08:32:16.327Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210594",
        "drugId": 210594,
        "drugPrimaryName": "Prograf (SOC)",
        "drugNameSynonyms": ["Prograf (SOC)"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425249],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-16T23:35:53.483Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210595",
        "drugId": 210595,
        "drugPrimaryName": "Prostaglandin analogue eye drops",
        "drugNameSynonyms": ["Prostaglandin analogue eye drops"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425257],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-16T23:36:00.203Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210596",
        "drugId": 210596,
        "drugPrimaryName": "Thrombolytic Agent",
        "drugNameSynonyms": ["Thrombolytic Agent"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425262],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-16T23:36:06.757Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210597",
        "drugId": 210597,
        "drugPrimaryName": "CBP-8008",
        "drugNameSynonyms": ["CBP 8008", "CBP-8008", "CBP8008"],
        "overview": "CBP-8008 is under development by Coherent Biopharma, using its C-PROTAC platform for the treatment of an undisclosed indication (Company pipeline, Coherent Biopharma, 17 Feb 2022, https://www.coherentbio.com/#/Pipeline; Company Web Page, Coherent Biopharma, 17 Feb 2022, https://www.coherentbio.com/#/Technology).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is in preclinical development (Company pipeline, Coherent Biopharma, 17 Feb 2022, https://www.coherentbio.com/#/Pipeline).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Coherent Biopharma",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "12836",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 20,
            "name": "NA/Unspecified",
            "indications": [
              {
                "diseaseName": "Undisclosed",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [],
                "drugIcd9": [],
                "drugIcd10": [],
                "drugSnomed": []
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-17T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-17T02:39:00.363Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Undisclosed",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Protein degrader",
            "mechanismSynonyms": [],
            "mechanismHierarchy": "Protein degrader"
          }],
        "deliveryRoutes": ["Unspecified"],
        "drugSupportingUrls": ["https://www.coherentbio.com/#/Pipeline", "https://www.coherentbio.com/#/Technology"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Chemical, synthetic",
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "China",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "China",
        "updatedDate": "2022-02-17T17:49:47.277Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210598",
        "drugId": 210598,
        "drugPrimaryName": "CBP-8018",
        "drugNameSynonyms": ["CBP 8018", "CBP-8018", "CBP8018"],
        "overview": "CBP-8018 is under development by Coherent Biopharma, using its C-PROTAC platform for the treatment of an undisclosed indication (Company pipeline, Coherent Biopharma, 17 Feb 2022, https://www.coherentbio.com/#/Pipeline; Company Web Page, Coherent Biopharma, 17 Feb 2022, https://www.coherentbio.com/#/Technology).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is in preclinical development (Company pipeline, Coherent Biopharma, 17 Feb 2022, https://www.coherentbio.com/#/Pipeline).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Coherent Biopharma",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "12836",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 20,
            "name": "NA/Unspecified",
            "indications": [
              {
                "diseaseName": "Undisclosed",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [],
                "drugIcd9": [],
                "drugIcd10": [],
                "drugSnomed": []
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-17T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-17T02:39:36.62Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Undisclosed",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Protein degrader",
            "mechanismSynonyms": [],
            "mechanismHierarchy": "Protein degrader"
          }],
        "deliveryRoutes": ["Unspecified"],
        "drugSupportingUrls": ["https://www.coherentbio.com/#/Pipeline", "https://www.coherentbio.com/#/Technology"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Chemical, synthetic",
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "China",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "China",
        "updatedDate": "2022-02-17T17:54:58.48Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210599",
        "drugId": 210599,
        "drugPrimaryName": "CBP-8028",
        "drugNameSynonyms": ["CBP 8028", "CBP-8028", "CBP8028"],
        "overview": "CBP-8028 is under development by Coherent Biopharma, using its C-PROTAC platform for the treatment of an undisclosed indication (Company pipeline, Coherent Biopharma, 17 Feb 2022, https://www.coherentbio.com/#/Pipeline; Company Web Page, Coherent Biopharma, 17 Feb 2022, https://www.coherentbio.com/#/Technology).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is in preclinical development (Company pipeline, Coherent Biopharma, 17 Feb 2022, https://www.coherentbio.com/#/Pipeline).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Coherent Biopharma",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "12836",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 20,
            "name": "NA/Unspecified",
            "indications": [
              {
                "diseaseName": "Undisclosed",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [],
                "drugIcd9": [],
                "drugIcd10": [],
                "drugSnomed": []
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-17T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-17T02:41:07.26Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Undisclosed",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Protein degrader",
            "mechanismSynonyms": [],
            "mechanismHierarchy": "Protein degrader"
          }],
        "deliveryRoutes": ["Unspecified"],
        "drugSupportingUrls": ["https://www.coherentbio.com/#/Pipeline", "https://www.coherentbio.com/#/Technology"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Chemical, synthetic",
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "China",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "China",
        "updatedDate": "2022-02-17T17:52:22.813Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210600",
        "drugId": 210600,
        "drugPrimaryName": "COVID-19 vaccine, OBI Pharma",
        "drugNameSynonyms": ["BCVax", "COVID-19 vaccine, OBI Pharma", "SARS-CoV2 vaccine, OBI Pharma"],
        "overview": "BCVax is a vaccine, under development by OBI Pharma using its recombinant protein technology against COVID-19 infection (Press release, OBI Pharma, 8 Feb 2022, https://www.obipharma.com/news/obi-pharma-announces-its-in-house-covid-19-vaccine-bcvax-can-induce-potent-antibodies-to-neutralize-against-all-variants/).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "In vivo\nIn animal studies, BCVax showed efficacy against the naive, Alpha, Beta, Gamma, Delta, and Omicron COVID virus and was proved to have better neutralizing effects (Press release, OBI Pharma, 8 Feb 2022, https://www.obipharma.com/news/obi-pharma-announces-its-in-house-covid-19-vaccine-bcvax-can-induce-potent-antibodies-to-neutralize-against-all-variants/).\n\nPatents\nA patent has been filed to USPTO (Press release, OBI Pharma, 8 Feb 2022, https://www.obipharma.com/news/obi-pharma-announces-its-in-house-covid-19-vaccine-bcvax-can-induce-potent-antibodies-to-neutralize-against-all-variants/).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "OBI Pharma",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "8266",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 11,
            "name": "Anti-infective Products",
            "indications": [
              {
                "diseaseName": "Infection, coronavirus, novel coronavirus prophylaxis",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D000086382",
                    "name": "COVID-19"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:V04.89",
                    "name": "Need for prophylactic vaccination and inoculation against other viral diseases"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "U07.1",
                    "name": "COVID-19"
                  }],
                "drugSnomed": []
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-08T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-17T03:11:12.687Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Prophylactic vaccine, anti-infective",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Recombinant vaccine",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Immunostimulant",
            "mechanismSynonyms": ["Immunogenic agent"],
            "mechanismHierarchy": "Immunostimulant"
          }],
        "deliveryRoutes": ["Injectable"],
        "drugSupportingUrls": ["https://www.obipharma.com/news/obi-pharma-announces-its-in-house-covid-19-vaccine-bcvax-can-induce-potent-antibodies-to-neutralize-against-all-variants/"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Biological, protein, recombinant",
        "casNumbers": [],
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "China",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Not applicable",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Not applicable"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "Taiwan, China",
        "updatedDate": "2022-02-17T03:15:33.55Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210601",
        "drugId": 210601,
        "drugPrimaryName": "LP-109C2-5/11",
        "drugNameSynonyms": ["LP 109C2-5/11", "LP-109C2-5/11", "LP109C2-5/11"],
        "overview": "LP-109C2-5/11 is under development by Laminar Pharma using its membrane lipid therapy (MLT) technology for the treatment of cancer (Company pipeline, Laminar Pharma, 17 Feb 2022, https://laminarpharma.com/products_/#over).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is at the discovery stage (Company pipeline, Laminar Pharma, 17 Feb 2022, https://laminarpharma.com/products_/#over).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Laminar Pharma",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "4112",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 12,
            "name": "Anticancer Products",
            "indications": [
              {
                "diseaseName": "Cancer, unspecified",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D009369",
                    "name": "Neoplasms"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:239",
                    "name": "Neoplasms of unspecified nature"
                  },
                  {
                    "icd9Id": "ICD9CM:338.3",
                    "name": "Neoplasm related pain (acute) (chronic)"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "C79.9",
                    "name": "Secondary malignant neoplasm of unspecified site"
                  },
                  {
                    "icd10Id": "C80.1",
                    "name": "Malignant (primary) neoplasm, unspecified"
                  },
                  {
                    "icd10Id": "D49.9",
                    "name": "Neoplasm of unspecified behavior of unspecified site"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED363346000",
                    "name": "Malignant tumour"
                  },
                  {
                    "snomedId": "SNOMED55342001",
                    "name": "Neoplastic disease"
                  }]
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-17T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-17T03:17:43.527Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Anticancer, other",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Unidentified pharmacological activity",
            "mechanismSynonyms": [],
            "mechanismHierarchy": "Unidentified pharmacological activity"
          }],
        "deliveryRoutes": ["Unspecified"],
        "drugSupportingUrls": ["https://laminarpharma.com/products_/#over"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Chemical, synthetic",
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "Spain",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "Spain",
        "updatedDate": "2022-02-17T03:20:04.917Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210602",
        "drugId": 210602,
        "drugPrimaryName": "abiraterone acetate (tablet),Chia Tai Tianqing Pharmaceutical Group Co",
        "drugNameSynonyms": ["abiraterone acetate (tablet),Chia Tai Tianqing Pharmaceutical Group Co"],
        "globalStatus": "Clinical Trial",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Anticancer, other",
            "therapeuticClassStatus": "Clinical Trial"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "17,20 lyase inhibitor",
            "mechanismSynonyms": ["17,20 desmolase inhibitor", "17alpha hydroxylase inhibitor", "CYP17A1 inhibitor", "Steroid 17alpha-monooxygenase inhibitor"],
            "mechanismHierarchy": "Lyase inhibitor:17,20 lyase inhibitor"
          },
          {
            "directMechanism": "Steroid synthesis inhibitor",
            "mechanismSynonyms": [],
            "mechanismHierarchy": "Steroid synthesis inhibitor"
          }],
        "deliveryRoutes": ["Oral"],
        "drugSupportingUrls": [],
        "deliveryMediums": ["Tablet"],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425024],
        "isPharmaProjectsDrug": "False",
        "drugSource": "NonClinicalTrials.gov",
        "updatedDate": "2022-02-17T03:57:52.46Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210603",
        "drugId": 210603,
        "drugPrimaryName": "anticancer radiotherapy, Ablaze Pharmaceuticals",
        "drugNameSynonyms": ["anticancer radiotherapy, Ablaze Pharmaceuticals"],
        "overview": "Ablaze Pharmaceuticals is developing an anticancer radiotherapy drug molecule, for the diagnosis and treatment of solid tumours by using its radioactive isotope (Company Web Page, Ablaze Pharmaceuticals, 17 Feb 2022, http://www.ablazepharma.com/en/product.html).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Ablaze Pharmaceuticals",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "19518",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 12,
            "name": "Anticancer",
            "indications": [
              {
                "diseaseName": "Diagnosis, cancer",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D003933",
                    "name": "Diagnosis"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:V82.9",
                    "name": "Screening for unspecified condition"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "C80.1",
                    "name": "Malignant (primary) neoplasm, unspecified"
                  },
                  {
                    "icd10Id": "D49.9",
                    "name": "Neoplasm of unspecified behavior of unspecified site"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED363346000",
                    "name": "Malignant tumour"
                  },
                  {
                    "snomedId": "SNOMED55342001",
                    "name": "Neoplastic disease"
                  }]
              },
              {
                "diseaseName": "Cancer, solid, unspecified",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D009369",
                    "name": "Neoplasms"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:140-239.99",
                    "name": "NEOPLASMS"
                  },
                  {
                    "icd9Id": "ICD9CM:199",
                    "name": "Malignant neoplasm without specification of site"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "C80.1",
                    "name": "Malignant (primary) neoplasm, unspecified"
                  },
                  {
                    "icd10Id": "D49.9",
                    "name": "Neoplasm of unspecified behavior of unspecified site"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED363346000",
                    "name": "Malignant tumour"
                  },
                  {
                    "snomedId": "SNOMED55342001",
                    "name": "Neoplastic disease"
                  }]
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-17T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-17T04:52:07.843Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Imaging agent",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Anticancer, other",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Radiopharmaceutical",
            "mechanismSynonyms": ["Medicinal radiocompound", "Radiocompound"],
            "mechanismHierarchy": "Radiopharmaceutical"
          }],
        "deliveryRoutes": ["Unspecified"],
        "drugSupportingUrls": ["http://www.ablazepharma.com/en/product.html"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Chemical, synthetic",
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "China",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "China",
        "updatedDate": "2022-02-18T13:58:23.513Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210604",
        "drugId": 210604,
        "drugPrimaryName": "atorvastatin + ezetimibe, Unimed Pharma",
        "drugNameSynonyms": ["atorvastatin + ezetimibe, Unimed Pharma", "atorvastatin/ezetimibe, Unimed Pharma", "ezetimibe + atorvastatin, Unimed Pharma", "ezetimibe/atorvastatin, Unimed Pharma", "Torvazet"],
        "globalStatus": "Clinical Trial",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Hypolipaemic/Antiatherosclerotic",
            "therapeuticClassStatus": "Clinical Trial"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Niemann-Pick C1-like 1 protein antagonist",
            "mechanismSynonyms": [],
            "mechanismHierarchy": "Niemann-Pick C1-like 1 protein antagonist"
          },
          {
            "directMechanism": "Cholesterol absorption inhibitor",
            "mechanismSynonyms": [],
            "mechanismHierarchy": "Cholesterol inhibitor:Cholesterol absorption inhibitor"
          },
          {
            "directMechanism": "HMGCoA reductase inhibitor",
            "mechanismSynonyms": ["HMGA reductase inhibitor", "Hydroxy methyl glutaric acid CoA reductase inhibitor"],
            "mechanismHierarchy": "Reductase inhibitor:HMGCoA reductase inhibitor"
          }],
        "deliveryRoutes": ["Oral", "Oral, swallowed"],
        "drugSupportingUrls": [],
        "deliveryMediums": ["Tablet"],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425029],
        "isPharmaProjectsDrug": "False",
        "drugSource": "NonClinicalTrials.gov",
        "updatedDate": "2022-02-17T06:05:25.1Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210605",
        "drugId": 210605,
        "drugPrimaryName": "pitavastatin calcium, Shandong New Time Pharmaceutical Co.",
        "drugNameSynonyms": ["pitavastatin calcium, Shandong New Time Pharmaceutical Co.", "pitavastatin, Shandong New Time Pharmaceutical Co."],
        "globalStatus": "Clinical Trial",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Hypolipaemic/Antiatherosclerotic",
            "therapeuticClassStatus": "Clinical Trial"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "HMGCoA reductase inhibitor",
            "mechanismSynonyms": ["HMGA reductase inhibitor", "Hydroxy methyl glutaric acid CoA reductase inhibitor"],
            "mechanismHierarchy": "Reductase inhibitor:HMGCoA reductase inhibitor"
          }],
        "deliveryRoutes": ["Oral", "Oral, swallowed"],
        "drugSupportingUrls": [],
        "deliveryMediums": ["Tablet"],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425018],
        "isPharmaProjectsDrug": "False",
        "drugSource": "NonClinicalTrials.gov",
        "updatedDate": "2022-02-17T06:42:36.533Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210606",
        "drugId": 210606,
        "drugPrimaryName": "Pur-NP",
        "drugNameSynonyms": ["Pur NP", "Pur-NP", "PurNP"],
        "overview": "PurMinds NeuroPharma is developing a nuclear pore targeted therapy for the treatment of amyotrophic lateral sclerosis (ALS), frontal temporal dementia (FTD), Huntington's disease (HD), Alzheimer's disease (AD) and traumatic brain injury (TBI), by using AI and machine learning technology (Company pipeline, PurMinds NeuroPharma, 17 Feb 2022, https://www.purminds.com/pipeline; Company Web Page, PurMinds NeuroPharma, 17 Feb 2022, https://www.purminds.com/technology).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is at the candidate selection stage (Company pipeline, PurMinds NeuroPharma, 17 Feb 2022, https://www.purminds.com/pipeline).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "PurMinds NeuroPharma",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "19573",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 14,
            "name": "Neurological",
            "indications": [
              {
                "diseaseName": "Amyotrophic lateral sclerosis",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D000690",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:335.20",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G12.21",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED86044005",
                    "name": "Amyotrophic lateral sclerosis"
                  }]
              },
              {
                "diseaseName": "Traumatic brain injury",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D000070642",
                    "name": "Brain Injuries, Traumatic"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:854.0-854.9",
                    "name": "Intracranial injury of other and unspecified nature without mention of open intracranial wound"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "S06.9",
                    "name": "Unspecified intracranial injury without loss of consciousness, episode of care unspecified"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED127295002",
                    "name": "Traumatic brain injury"
                  }]
              },
              {
                "diseaseName": "Alzheimer's disease",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D000544",
                    "name": "Alzheimer Disease"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:290.1",
                    "name": "Presenile dementia"
                  },
                  {
                    "icd9Id": "ICD9CM:331.0",
                    "name": "Alzheimer's disease"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G30.9",
                    "name": "Alzheimer's disease, unspecified"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED26929004",
                    "name": "Alzheimer's disease"
                  }]
              },
              {
                "diseaseName": "Huntington's disease",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D006816",
                    "name": "Huntington Disease"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:333.4",
                    "name": "Huntington's chorea"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G10",
                    "name": "Huntington's disease"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED58756001",
                    "name": "Huntington's chorea"
                  }]
              },
              {
                "diseaseName": "Dementia, frontotemporal",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D057180",
                    "name": "Frontotemporal Dementia"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:331.19",
                    "name": "Other frontotemporal dementia"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G31.09",
                    "name": "Other frontotemporal dementia"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED230270009",
                    "name": "Frontotemporal dementia"
                  }]
              }]
          },
          {
            "id": 24,
            "name": "Rare Diseases",
            "indications": [
              {
                "diseaseName": "Amyotrophic lateral sclerosis",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D000690",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:335.20",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G12.21",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED86044005",
                    "name": "Amyotrophic lateral sclerosis"
                  }]
              },
              {
                "diseaseName": "Huntington's disease",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D006816",
                    "name": "Huntington Disease"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:333.4",
                    "name": "Huntington's chorea"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G10",
                    "name": "Huntington's disease"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED58756001",
                    "name": "Huntington's chorea"
                  }]
              },
              {
                "diseaseName": "Dementia, frontotemporal",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D057180",
                    "name": "Frontotemporal Dementia"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:331.19",
                    "name": "Other frontotemporal dementia"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G31.09",
                    "name": "Other frontotemporal dementia"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED230270009",
                    "name": "Frontotemporal dementia"
                  }]
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-17T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-17T08:01:39.017Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Antiparkinsonian",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Cognition enhancer",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Neuroprotective",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Unidentified pharmacological activity",
            "mechanismSynonyms": [],
            "mechanismHierarchy": "Unidentified pharmacological activity"
          }],
        "deliveryRoutes": ["Unspecified"],
        "drugSupportingUrls": ["https://www.purminds.com/pipeline", "https://www.purminds.com/technology"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Chemical, synthetic",
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "Canada",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "Canada",
        "updatedDate": "2022-02-21T06:05:17.16Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210607",
        "drugId": 210607,
        "drugPrimaryName": "first-generation psychedelics, PurMinds NeuroPharma",
        "drugNameSynonyms": ["first-generation psychedelics, PurMinds NeuroPharma", "Pur 1P", "Pur-1P", "Pur1P"],
        "overview": "PurMinds NeuroPharma is developing first-generation psychedelics for the treatment of amyotrophic lateral sclerosis (ALS), frontal temporal dementia (FTD), Huntington's disease (HD), Alzheimer's disease (AD) and traumatic brain injury (TBI) by using AI and machine learning technology (Company pipeline, PurMinds NeuroPharma, 17 Feb 2022, https://www.purminds.com/pipeline; Company Web Page, PurMinds NeuroPharma, 17 Feb 2022, https://www.purminds.com/technology).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is at the lead optimization stage (Company pipeline, PurMinds NeuroPharma, 17 Feb 2022, https://www.purminds.com/pipeline).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "PurMinds NeuroPharma",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "19573",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 14,
            "name": "Neurological Products",
            "indications": [
              {
                "diseaseName": "Amyotrophic lateral sclerosis",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D000690",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:335.20",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G12.21",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED86044005",
                    "name": "Amyotrophic lateral sclerosis"
                  }]
              },
              {
                "diseaseName": "Traumatic brain injury",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D000070642",
                    "name": "Brain Injuries, Traumatic"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:854.0-854.9",
                    "name": "Intracranial injury of other and unspecified nature without mention of open intracranial wound"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "S06.9",
                    "name": "Unspecified intracranial injury without loss of consciousness, episode of care unspecified"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED127295002",
                    "name": "Traumatic brain injury"
                  }]
              },
              {
                "diseaseName": "Alzheimer's disease",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D000544",
                    "name": "Alzheimer Disease"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:290.1",
                    "name": "Presenile dementia"
                  },
                  {
                    "icd9Id": "ICD9CM:331.0",
                    "name": "Alzheimer's disease"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G30.9",
                    "name": "Alzheimer's disease, unspecified"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED26929004",
                    "name": "Alzheimer's disease"
                  }]
              },
              {
                "diseaseName": "Huntington's disease",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D006816",
                    "name": "Huntington Disease"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:333.4",
                    "name": "Huntington's chorea"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G10",
                    "name": "Huntington's disease"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED58756001",
                    "name": "Huntington's chorea"
                  }]
              },
              {
                "diseaseName": "Dementia, frontotemporal",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D057180",
                    "name": "Frontotemporal Dementia"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:331.19",
                    "name": "Other frontotemporal dementia"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G31.09",
                    "name": "Other frontotemporal dementia"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED230270009",
                    "name": "Frontotemporal dementia"
                  }]
              }]
          },
          {
            "id": 24,
            "name": "Rare Diseases",
            "indications": [
              {
                "diseaseName": "Amyotrophic lateral sclerosis",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D000690",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:335.20",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G12.21",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED86044005",
                    "name": "Amyotrophic lateral sclerosis"
                  }]
              },
              {
                "diseaseName": "Huntington's disease",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D006816",
                    "name": "Huntington Disease"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:333.4",
                    "name": "Huntington's chorea"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G10",
                    "name": "Huntington's disease"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED58756001",
                    "name": "Huntington's chorea"
                  }]
              },
              {
                "diseaseName": "Dementia, frontotemporal",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D057180",
                    "name": "Frontotemporal Dementia"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:331.19",
                    "name": "Other frontotemporal dementia"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G31.09",
                    "name": "Other frontotemporal dementia"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED230270009",
                    "name": "Frontotemporal dementia"
                  }]
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-17T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-17T07:11:50.4Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Antiparkinsonian",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Cognition enhancer",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Neuroprotective",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Unidentified pharmacological activity",
            "mechanismSynonyms": [],
            "mechanismHierarchy": "Unidentified pharmacological activity"
          }],
        "deliveryRoutes": ["Unspecified"],
        "drugSupportingUrls": ["https://www.purminds.com/pipeline", "https://www.purminds.com/technology"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Chemical, synthetic",
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "Canada",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "Canada",
        "updatedDate": "2022-02-17T08:04:15.173Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210608",
        "drugId": 210608,
        "drugPrimaryName": "dabigatran etexilate, Canonpharma",
        "drugNameSynonyms": ["dabigatran etexilate, Canonpharma", "dabigatran, Canonpharma"],
        "globalStatus": "Clinical Trial",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Antithrombotic, anticoagulant",
            "therapeuticClassStatus": "Clinical Trial"
          },
          {
            "therapeuticClassName": "Neuroprotective",
            "therapeuticClassStatus": "Clinical Trial"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Direct thrombin inhibitor",
            "mechanismSynonyms": [],
            "mechanismHierarchy": "Clotting factor inhibitor:Thrombin inhibitor:Direct thrombin inhibitor"
          },
          {
            "directMechanism": "Serine protease inhibitor",
            "mechanismSynonyms": ["General serine protease inhibitor", "General serine proteinase inhibitor", "Serine proteinase unspecified inhibitor", "Unspecified serine protease inhibitor"],
            "mechanismHierarchy": "Protease/peptidase inhibitor:Serine protease inhibitor"
          }],
        "deliveryRoutes": ["Oral", "Oral, swallowed"],
        "drugSupportingUrls": [],
        "deliveryMediums": ["Capsule, hard"],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425176],
        "isPharmaProjectsDrug": "False",
        "drugSource": "NonClinicalTrials.gov",
        "updatedDate": "2022-02-17T07:18:17.183Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210609",
        "drugId": 210609,
        "drugPrimaryName": "psychedelic therapy, PurMinds NeuroPharma",
        "drugNameSynonyms": ["psychedelic therapy, PurMinds NeuroPharma", "Pur PD", "Pur-PD", "PurPD"],
        "overview": "PurMinds NeuroPharma is developing psychedelic derivatives for the treatment of amyotrophic lateral sclerosis (ALS), frontal temporal dementia (FTD), Huntington's disease (HD), Alzheimer's disease (AD) and traumatic brain injury (TBI) by using AI and machine learning technology (Company pipeline, PurMinds NeuroPharma, 17 Feb 2022, https://www.purminds.com/pipeline; Company Web Page, PurMinds NeuroPharma, 17 Feb 2022, https://www.purminds.com/technology).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is at the candiate selection stage (Company pipeline, PurMinds NeuroPharma, 17 Feb 2022, https://www.purminds.com/pipeline).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "PurMinds NeuroPharma",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "19573",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 14,
            "name": "Neurological Products",
            "indications": [
              {
                "diseaseName": "Amyotrophic lateral sclerosis",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D000690",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:335.20",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G12.21",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED86044005",
                    "name": "Amyotrophic lateral sclerosis"
                  }]
              },
              {
                "diseaseName": "Traumatic brain injury",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D000070642",
                    "name": "Brain Injuries, Traumatic"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:854.0-854.9",
                    "name": "Intracranial injury of other and unspecified nature without mention of open intracranial wound"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "S06.9",
                    "name": "Unspecified intracranial injury without loss of consciousness, episode of care unspecified"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED127295002",
                    "name": "Traumatic brain injury"
                  }]
              },
              {
                "diseaseName": "Alzheimer's disease",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D000544",
                    "name": "Alzheimer Disease"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:290.1",
                    "name": "Presenile dementia"
                  },
                  {
                    "icd9Id": "ICD9CM:331.0",
                    "name": "Alzheimer's disease"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G30.9",
                    "name": "Alzheimer's disease, unspecified"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED26929004",
                    "name": "Alzheimer's disease"
                  }]
              },
              {
                "diseaseName": "Huntington's disease",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D006816",
                    "name": "Huntington Disease"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:333.4",
                    "name": "Huntington's chorea"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G10",
                    "name": "Huntington's disease"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED58756001",
                    "name": "Huntington's chorea"
                  }]
              },
              {
                "diseaseName": "Dementia, frontotemporal",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D057180",
                    "name": "Frontotemporal Dementia"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:331.19",
                    "name": "Other frontotemporal dementia"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G31.09",
                    "name": "Other frontotemporal dementia"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED230270009",
                    "name": "Frontotemporal dementia"
                  }]
              }]
          },
          {
            "id": 24,
            "name": "Rare Diseases",
            "indications": [
              {
                "diseaseName": "Amyotrophic lateral sclerosis",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D000690",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:335.20",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G12.21",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED86044005",
                    "name": "Amyotrophic lateral sclerosis"
                  }]
              },
              {
                "diseaseName": "Huntington's disease",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D006816",
                    "name": "Huntington Disease"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:333.4",
                    "name": "Huntington's chorea"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G10",
                    "name": "Huntington's disease"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED58756001",
                    "name": "Huntington's chorea"
                  }]
              },
              {
                "diseaseName": "Dementia, frontotemporal",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D057180",
                    "name": "Frontotemporal Dementia"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:331.19",
                    "name": "Other frontotemporal dementia"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G31.09",
                    "name": "Other frontotemporal dementia"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED230270009",
                    "name": "Frontotemporal dementia"
                  }]
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-17T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-17T07:30:44.6Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Antiparkinsonian",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Cognition enhancer",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Neuroprotective",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Unidentified pharmacological activity",
            "mechanismSynonyms": [],
            "mechanismHierarchy": "Unidentified pharmacological activity"
          }],
        "deliveryRoutes": ["Unspecified"],
        "drugSupportingUrls": ["https://www.purminds.com/pipeline", "https://www.purminds.com/technology"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Chemical, synthetic",
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "Canada",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "Canada",
        "updatedDate": "2022-02-17T08:06:41.947Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210610",
        "drugId": 210610,
        "drugPrimaryName": "Pur-MF",
        "drugNameSynonyms": ["Pur MF", "Pur-MF", "PurMF"],
        "overview": "PurMinds NeuroPharma is developing a mitochondrial fission therapy for the treatment of Parkinson's disease (PD) by using AI and machine learning technology (Company pipeline, PurMinds NeuroPharma, 17 Feb 2022, https://www.purminds.com/pipeline; Company Web Page, PurMinds NeuroPharma, 17 Feb 2022, https://www.purminds.com/technology).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is at the candidate selection stage (Company pipeline, PurMinds NeuroPharma, 17 Feb 2022, https://www.purminds.com/pipeline).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "PurMinds NeuroPharma",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "19573",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 14,
            "name": "Neurological Products",
            "indications": [
              {
                "diseaseName": "Parkinson's disease",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D010300",
                    "name": "Parkinson Disease"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:332",
                    "name": "Parkinson's disease"
                  },
                  {
                    "icd9Id": "ICD9CM:332.0",
                    "name": "Paralysis agitans"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G20",
                    "name": "Parkinson's disease"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED49049000",
                    "name": "Parkinson's disease"
                  }]
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-17T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-17T08:21:24.077Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Antiparkinsonian",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Unidentified pharmacological activity",
            "mechanismSynonyms": [],
            "mechanismHierarchy": "Unidentified pharmacological activity"
          }],
        "deliveryRoutes": ["Unspecified"],
        "drugSupportingUrls": ["https://www.purminds.com/pipeline", "https://www.purminds.com/technology"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Chemical, synthetic",
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "Canada",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "Canada",
        "updatedDate": "2022-02-17T08:21:24.153Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210611",
        "drugId": 210611,
        "drugPrimaryName": "esomeprazole magnesium, Mantra Pharma",
        "drugNameSynonyms": ["esomeprazole magnesium, Mantra Pharma", "esomeprazole, Mantra Pharma"],
        "globalStatus": "Clinical Trial",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [
          {
            "therapeuticClassName": "GI inflammatory/bowel disorders",
            "therapeuticClassStatus": "Clinical Trial"
          },
          {
            "therapeuticClassName": "Antispasmodic",
            "therapeuticClassStatus": "Clinical Trial"
          },
          {
            "therapeuticClassName": "Antiulcer",
            "therapeuticClassStatus": "Clinical Trial"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "H+ K+ transporting ATPase inhibitor",
            "mechanismSynonyms": ["ATP phosphohydrolase H+ K+ transporting inhibitor", "H K transporting ATPase inhibitor", "PPI", "Proton pump inhibitor"],
            "mechanismHierarchy": "Hydrolase inhibitor:H+ K+ transporting ATPase inhibitor"
          }],
        "deliveryRoutes": ["Oral", "Oral, swallowed"],
        "drugSupportingUrls": [],
        "deliveryMediums": ["Tablet"],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425186, 425191],
        "isPharmaProjectsDrug": "False",
        "drugSource": "NonClinicalTrials.gov",
        "updatedDate": "2022-02-17T07:47:18.55Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210613",
        "drugId": 210613,
        "drugPrimaryName": "Pur-NV",
        "drugNameSynonyms": ["Pur NV", "Pur-NV", "PurNV"],
        "overview": "PurMinds NeuroPharma is developing Phyto extract for the treatment of amyotrophic lateral sclerosis (ALS) and Alzheimer's disease (AD) by using AI and machine learning technology (Company pipeline, PurMinds NeuroPharma, 21 Feb 2022, https://www.purminds.com/pipeline; Company Web Page, PurMinds NeuroPharma, 17 Feb 2022, https://www.purminds.com/technology).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is at the lead optimization stage (Company pipeline, PurMinds NeuroPharma, 21 Feb 2022, https://www.purminds.com/pipeline).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "PurMinds NeuroPharma",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "19573",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 14,
            "name": "Neurological",
            "indications": [
              {
                "diseaseName": "Amyotrophic lateral sclerosis",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D000690",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:335.20",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G12.21",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED86044005",
                    "name": "Amyotrophic lateral sclerosis"
                  }]
              },
              {
                "diseaseName": "Alzheimer's disease",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D000544",
                    "name": "Alzheimer Disease"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:290.1",
                    "name": "Presenile dementia"
                  },
                  {
                    "icd9Id": "ICD9CM:331.0",
                    "name": "Alzheimer's disease"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G30.9",
                    "name": "Alzheimer's disease, unspecified"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED26929004",
                    "name": "Alzheimer's disease"
                  }]
              }]
          },
          {
            "id": 24,
            "name": "Rare Diseases",
            "indications": [
              {
                "diseaseName": "Amyotrophic lateral sclerosis",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D000690",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:335.20",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G12.21",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED86044005",
                    "name": "Amyotrophic lateral sclerosis"
                  }]
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-21T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-21T10:28:51.483Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Cognition enhancer",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Neuroprotective",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Unidentified pharmacological activity",
            "mechanismSynonyms": [],
            "mechanismHierarchy": "Unidentified pharmacological activity"
          }],
        "deliveryRoutes": ["Unspecified"],
        "drugSupportingUrls": ["https://www.purminds.com/pipeline", "https://www.purminds.com/technology"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Natural product, plant",
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "Canada",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "Canada",
        "updatedDate": "2022-02-21T10:28:51.58Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210614",
        "drugId": 210614,
        "drugPrimaryName": "Pur XX-01",
        "drugNameSynonyms": ["Pur XX 01", "Pur XX-01", "Pur XX01"],
        "overview": "Pur XX-01 is under development by PurMinds NeuroPharma using AI and machine learning technology for the treatment of amyotrophic lateral sclerosis (ALS), frontal temporal dementia (FTD), Huntington's disease (HD), Alzheimer's disease (AD), traumatic brain injury (TBI) and Parkinson's disease (Company pipeline, PurMinds NeuroPharma, 21 Feb 2022, https://www.purminds.com/pipeline; Company Web Page, PurMinds NeuroPharma, 21 Feb 2022, https://www.purminds.com/technology).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is at the pre-IND stage (Company pipeline, PurMinds NeuroPharma, 21 Feb 2022, https://www.purminds.com/pipeline).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "PurMinds NeuroPharma",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "19573",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 14,
            "name": "Neurological",
            "indications": [
              {
                "diseaseName": "Amyotrophic lateral sclerosis",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D000690",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:335.20",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G12.21",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED86044005",
                    "name": "Amyotrophic lateral sclerosis"
                  }]
              },
              {
                "diseaseName": "Traumatic brain injury",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D000070642",
                    "name": "Brain Injuries, Traumatic"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:854.0-854.9",
                    "name": "Intracranial injury of other and unspecified nature without mention of open intracranial wound"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "S06.9",
                    "name": "Unspecified intracranial injury without loss of consciousness, episode of care unspecified"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED127295002",
                    "name": "Traumatic brain injury"
                  }]
              },
              {
                "diseaseName": "Parkinson's disease",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D010300",
                    "name": "Parkinson Disease"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:332",
                    "name": "Parkinson's disease"
                  },
                  {
                    "icd9Id": "ICD9CM:332.0",
                    "name": "Paralysis agitans"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G20",
                    "name": "Parkinson's disease"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED49049000",
                    "name": "Parkinson's disease"
                  }]
              },
              {
                "diseaseName": "Alzheimer's disease",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D000544",
                    "name": "Alzheimer Disease"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:290.1",
                    "name": "Presenile dementia"
                  },
                  {
                    "icd9Id": "ICD9CM:331.0",
                    "name": "Alzheimer's disease"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G30.9",
                    "name": "Alzheimer's disease, unspecified"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED26929004",
                    "name": "Alzheimer's disease"
                  }]
              },
              {
                "diseaseName": "Huntington's disease",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D006816",
                    "name": "Huntington Disease"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:333.4",
                    "name": "Huntington's chorea"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G10",
                    "name": "Huntington's disease"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED58756001",
                    "name": "Huntington's chorea"
                  }]
              },
              {
                "diseaseName": "Dementia, frontotemporal",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D057180",
                    "name": "Frontotemporal Dementia"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:331.19",
                    "name": "Other frontotemporal dementia"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G31.09",
                    "name": "Other frontotemporal dementia"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED230270009",
                    "name": "Frontotemporal dementia"
                  }]
              }]
          },
          {
            "id": 24,
            "name": "Rare Diseases",
            "indications": [
              {
                "diseaseName": "Amyotrophic lateral sclerosis",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D000690",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:335.20",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G12.21",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED86044005",
                    "name": "Amyotrophic lateral sclerosis"
                  }]
              },
              {
                "diseaseName": "Huntington's disease",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D006816",
                    "name": "Huntington Disease"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:333.4",
                    "name": "Huntington's chorea"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G10",
                    "name": "Huntington's disease"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED58756001",
                    "name": "Huntington's chorea"
                  }]
              },
              {
                "diseaseName": "Dementia, frontotemporal",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D057180",
                    "name": "Frontotemporal Dementia"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:331.19",
                    "name": "Other frontotemporal dementia"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G31.09",
                    "name": "Other frontotemporal dementia"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED230270009",
                    "name": "Frontotemporal dementia"
                  }]
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-21T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-21T16:38:54.563Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Antiparkinsonian",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Cognition enhancer",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Neuroprotective",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Unidentified pharmacological activity",
            "mechanismSynonyms": [],
            "mechanismHierarchy": "Unidentified pharmacological activity"
          }],
        "deliveryRoutes": ["Unspecified"],
        "drugSupportingUrls": ["https://www.purminds.com/pipeline", "https://www.purminds.com/technology"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Chemical, synthetic",
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "Canada",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "Canada",
        "updatedDate": "2022-02-21T16:38:54.657Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210615",
        "drugId": 210615,
        "drugPrimaryName": "Pur XX02",
        "drugNameSynonyms": ["Pur XX-02", "Pur XX02", "Pur XXv02"],
        "overview": "Pur XX-02 is under development by PurMinds NeuroPharma using AI and machine learning technology for the treatment of amyotrophic lateral sclerosis (ALS), frontal temporal dementia (FTD), Huntington's disease (HD), Alzheimer's disease (AD), traumatic brain injury (TBI) and Parkinson's disease (Company pipeline, PurMinds NeuroPharma, 21 Feb 2022, https://www.purminds.com/pipeline; Company Web Page, PurMinds NeuroPharma, 21 Feb 2022, https://www.purminds.com/technology).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is at the pre-IND stage (Company pipeline, PurMinds NeuroPharma, 21 Feb 2022, https://www.purminds.com/pipeline).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "PurMinds NeuroPharma",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "19573",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 14,
            "name": "Neurological",
            "indications": [
              {
                "diseaseName": "Amyotrophic lateral sclerosis",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D000690",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:335.20",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G12.21",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED86044005",
                    "name": "Amyotrophic lateral sclerosis"
                  }]
              },
              {
                "diseaseName": "Traumatic brain injury",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D000070642",
                    "name": "Brain Injuries, Traumatic"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:854.0-854.9",
                    "name": "Intracranial injury of other and unspecified nature without mention of open intracranial wound"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "S06.9",
                    "name": "Unspecified intracranial injury without loss of consciousness, episode of care unspecified"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED127295002",
                    "name": "Traumatic brain injury"
                  }]
              },
              {
                "diseaseName": "Parkinson's disease",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D010300",
                    "name": "Parkinson Disease"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:332",
                    "name": "Parkinson's disease"
                  },
                  {
                    "icd9Id": "ICD9CM:332.0",
                    "name": "Paralysis agitans"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G20",
                    "name": "Parkinson's disease"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED49049000",
                    "name": "Parkinson's disease"
                  }]
              },
              {
                "diseaseName": "Alzheimer's disease",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D000544",
                    "name": "Alzheimer Disease"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:290.1",
                    "name": "Presenile dementia"
                  },
                  {
                    "icd9Id": "ICD9CM:331.0",
                    "name": "Alzheimer's disease"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G30.9",
                    "name": "Alzheimer's disease, unspecified"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED26929004",
                    "name": "Alzheimer's disease"
                  }]
              },
              {
                "diseaseName": "Huntington's disease",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D006816",
                    "name": "Huntington Disease"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:333.4",
                    "name": "Huntington's chorea"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G10",
                    "name": "Huntington's disease"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED58756001",
                    "name": "Huntington's chorea"
                  }]
              },
              {
                "diseaseName": "Dementia, frontotemporal",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D057180",
                    "name": "Frontotemporal Dementia"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:331.19",
                    "name": "Other frontotemporal dementia"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G31.09",
                    "name": "Other frontotemporal dementia"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED230270009",
                    "name": "Frontotemporal dementia"
                  }]
              }]
          },
          {
            "id": 24,
            "name": "Rare Diseases",
            "indications": [
              {
                "diseaseName": "Amyotrophic lateral sclerosis",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D000690",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:335.20",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G12.21",
                    "name": "Amyotrophic lateral sclerosis"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED86044005",
                    "name": "Amyotrophic lateral sclerosis"
                  }]
              },
              {
                "diseaseName": "Huntington's disease",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D006816",
                    "name": "Huntington Disease"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:333.4",
                    "name": "Huntington's chorea"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G10",
                    "name": "Huntington's disease"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED58756001",
                    "name": "Huntington's chorea"
                  }]
              },
              {
                "diseaseName": "Dementia, frontotemporal",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D057180",
                    "name": "Frontotemporal Dementia"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:331.19",
                    "name": "Other frontotemporal dementia"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "G31.09",
                    "name": "Other frontotemporal dementia"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED230270009",
                    "name": "Frontotemporal dementia"
                  }]
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-21T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-21T16:44:31.623Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Antiparkinsonian",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Cognition enhancer",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Neuroprotective",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Unidentified pharmacological activity",
            "mechanismSynonyms": [],
            "mechanismHierarchy": "Unidentified pharmacological activity"
          }],
        "deliveryRoutes": ["Unspecified"],
        "drugSupportingUrls": ["https://www.purminds.com/pipeline", "https://www.purminds.com/technology"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Chemical, synthetic",
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "Canada",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "Canada",
        "updatedDate": "2022-02-21T16:44:31.72Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210616",
        "drugId": 210616,
        "drugPrimaryName": "ARO-ENaC2",
        "drugNameSynonyms": ["ARO ENaC2", "ARO-ENaC2", "AROENaC2"],
        "overview": "ARO-ENaC2 is a RNA interference therapeutic targeting the epithelial sodium channel alpha subunit (aENaC), under developmment by Arrowhead Pharmaceuticals for the treatment of cystic fibrosis (Company pipeline, Arrowhead Pharmaceuticals, 17 Feb 2022, https://arrowheadpharma.com/pipeline/; Company Web Page, Arrowhead Pharmaceuticals, 17 Feb 2022, https://arrowheadpharma.com/about/).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is in preclinical development (Company pipeline, Arrowhead Pharmaceuticals, 17 Feb 2022, https://arrowheadpharma.com/pipeline/).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Arrowhead Pharmaceuticals",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "8103",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 16,
            "name": "Respiratory Products",
            "indications": [
              {
                "diseaseName": "Cystic fibrosis",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D003550",
                    "name": "Cystic Fibrosis"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:277.0",
                    "name": "Cystic fibrosis"
                  },
                  {
                    "icd9Id": "ICD9CM:277.00",
                    "name": "Cystic fibrosis without mention of meconium ileus"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "E84.9",
                    "name": "Cystic fibrosis, unspecified"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED190905008",
                    "name": "Cystic fibrosis"
                  }]
              }]
          },
          {
            "id": 24,
            "name": "Rare Diseases",
            "indications": [
              {
                "diseaseName": "Cystic fibrosis",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D003550",
                    "name": "Cystic Fibrosis"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:277.0",
                    "name": "Cystic fibrosis"
                  },
                  {
                    "icd9Id": "ICD9CM:277.00",
                    "name": "Cystic fibrosis without mention of meconium ileus"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "E84.9",
                    "name": "Cystic fibrosis, unspecified"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED190905008",
                    "name": "Cystic fibrosis"
                  }]
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-17T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-17T10:23:56.28Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Cystic fibrosis treatment",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "RNA interference",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Epithelial sodium channel antagonist",
            "mechanismSynonyms": [],
            "mechanismHierarchy": "Ion channel antagonist:Sodium channel antagonist:Epithelial sodium channel antagonist"
          },
          {
            "directMechanism": "Gene expression inhibitor",
            "mechanismSynonyms": ["Gene promoter inhibitor", "General transcription inhibitor", "General translation inhibitor"],
            "mechanismHierarchy": "Gene expression inhibitor"
          }],
        "deliveryRoutes": ["Unspecified"],
        "drugSupportingUrls": ["https://arrowheadpharma.com/about/", "https://arrowheadpharma.com/pipeline/", "https://ir.arrowheadpharma.com/static-files/e9d35e6e-643d-4712-83da-ff51a434c077"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Chemical, synthetic, nucleic acid",
        "casNumbers": [],
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "USA",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "sodium channel epithelial 1 alpha subunit",
            "entrezGeneId": 6337,
            "targetFamilies": ["Ion channel > Sodium channel"],
            "targetECNumbers": [],
            "targetSynonyms": ["amiloride-sensitive epithelial sodium channel alpha subunit", "amiloride-sensitive sodium channel subunit alpha 2", "BESC2", "ENaCa", "ENaCalpha", "FLJ21883", "nasal epithelial sodium channel alpha subunit", "SCNEA", "SCNN1", "SCNN1A", "sodium channel, epithelial, alpha subunit", "sodium channel, non-voltage-gated 1 alpha subunit", "sodium channel, nonvoltage-gated 1 alpha"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "USA",
        "updatedDate": "2022-02-17T10:23:56.373Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210617",
        "drugId": 210617,
        "drugPrimaryName": "ARO-MUC5AC",
        "drugNameSynonyms": ["ARO MUC5AC", "ARO-MUC5AC", "AROMUC5AC"],
        "overview": "ARO-MUC5AC is a RNA interference therapeutic targeting MUC5AC, under developmment by Arrowhead Pharmaceuticals for the treatment of various muco-obstructive and inflammatory pulmonary diseases like asthma (Company pipeline, Arrowhead, 21 Feb 2022, https://arrowheadpharma.com/pipeline/; Company Web Page, Arrowhead Pharmaceuticals, 21 Feb 2022, https://arrowheadpharma.com/about/; Transcript, Arrowhead Pharmaceuticals, 2 Feb 2022, Page 14, https://ir.arrowheadpharma.com/static-files/e9d35e6e-643d-4712-83da-ff51a434c077).",
        "marketing": "",
        "licensing": "",
        "phaseI": "A CTA filing is expected in the 2nd qtr of 2022 (Transcript, Arrowhead Pharmaceuticals, 2 Feb 2022, Page 7, https://ir.arrowheadpharma.com/static-files/e9d35e6e-643d-4712-83da-ff51a434c077).",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is in preclinical development (Company pipeline, Arrowhead, 21 Feb 2022, https://arrowheadpharma.com/pipeline/).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Arrowhead Pharmaceuticals",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "8103",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 16,
            "name": "Respiratory",
            "indications": [
              {
                "diseaseName": "Asthma",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D001249",
                    "name": "Asthma"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:493",
                    "name": "Asthma"
                  },
                  {
                    "icd9Id": "ICD9CM:493.9",
                    "name": "Asthma, unspecified"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "J45.909",
                    "name": "Unspecified asthma, uncomplicated"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED195967001",
                    "name": "Airway hyperreactivity"
                  }]
              },
              {
                "diseaseName": "Respiratory disease, unspecified",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D012120",
                    "name": "Respiration Disorders"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:519.9",
                    "name": "Unspecified disease of respiratory system"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "J98.9",
                    "name": "Respiratory disorder, unspecified"
                  },
                  {
                    "icd10Id": "P28.9",
                    "name": "Respiratory condition of newborn, unspecified"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED50043002",
                    "name": "Respiratory disorder"
                  }]
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-21T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          },
          {
            "keyEventDate": "2022-02-21T00:00:00Z",
            "keyEventHistory": "Novel Target Identified",
            "keyEventDetail": "mucin 5AC, oligomeric mucus/gel-forming (4586)"
          }],
        "latestChangeDate": "2022-02-21T16:57:06.317Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Antiasthma",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Respiratory",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "RNA interference",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Gene expression inhibitor",
            "mechanismSynonyms": ["Gene promoter inhibitor", "General translation inhibitor", "General transcription inhibitor"],
            "mechanismHierarchy": "Gene expression inhibitor"
          },
          {
            "directMechanism": "MUC-5AC inhibitor",
            "mechanismSynonyms": ["Mucin 5AC inhibitor"],
            "mechanismHierarchy": "MUC inhibitor:MUC-5AC inhibitor"
          }],
        "deliveryRoutes": ["Unspecified"],
        "drugSupportingUrls": ["https://arrowheadpharma.com/about/", "https://arrowheadpharma.com/pipeline/", "https://ir.arrowheadpharma.com/static-files/e9d35e6e-643d-4712-83da-ff51a434c077"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Chemical, synthetic, nucleic acid",
        "casNumbers": [],
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "USA",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "mucin 5AC, oligomeric mucus/gel-forming",
            "entrezGeneId": 4586,
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["gastric mucin", "leB", "lewis B blood group antigen", "major airway glycoprotein", "MUC5", "MUC5AC", "mucin", "mucin 5, subtypes A and C, tracheobronchial/gastric", "mucin-5 subtype AC, tracheobronchial", "mucin-5AC", "TBM", "tracheobronchial mucin"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "USA",
        "updatedDate": "2022-02-21T16:57:50.997Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210618",
        "drugId": 210618,
        "drugPrimaryName": "ARO-RAGE",
        "drugNameSynonyms": ["ARO RAGE", "ARO-RAGE", "ARORAGE"],
        "overview": "ARO-RAGE is a RNA interference therapeutic targeting expression of RAGE, under developmment by Arrowhead Pharmaceuticals for the treatment of various muco-obstructive and inflammatory pulmonary diseases like asthma (Company pipeline, Arrowhead, 17 Feb 2022, https://arrowheadpharma.com/pipeline/; Company Web Page, Arrowhead Pharmaceuticals, 17 Feb 2022, https://arrowheadpharma.com/about/; Transcript, Arrowhead Pharmaceuticals, 2 Feb 2022, Page 15, https://ir.arrowheadpharma.com/static-files/e9d35e6e-643d-4712-83da-ff51a434c077).",
        "marketing": "",
        "licensing": "",
        "phaseI": "A CTA filing is expected in the 2nd qtr of 2022 (Transcript, Arrowhead Pharmaceuticals, 2 Feb 2022, Page 7, https://ir.arrowheadpharma.com/static-files/e9d35e6e-643d-4712-83da-ff51a434c077).",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is in preclinical development (ompany pipeline, Arrowhead, 17 Feb 2022, https://arrowheadpharma.com/pipeline/).\n\nIn vivo\nIn rats using a tool trigger targeting RAGE mRNA, single inhaled doses of 0.5mg/kg induced sRAGE reduction of over 90% lasting for approximately three months (Transcript, Arrowhead Pharmaceuticals, 2 Feb 2022, Page 16, https://ir.arrowheadpharma.com/static-files/e9d35e6e-643d-4712-83da-ff51a434c077).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Arrowhead Pharmaceuticals",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "8103",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 16,
            "name": "Respiratory",
            "indications": [
              {
                "diseaseName": "Asthma",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D001249",
                    "name": "Asthma"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:493",
                    "name": "Asthma"
                  },
                  {
                    "icd9Id": "ICD9CM:493.9",
                    "name": "Asthma, unspecified"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "J45.909",
                    "name": "Unspecified asthma, uncomplicated"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED195967001",
                    "name": "Airway hyperreactivity"
                  }]
              },
              {
                "diseaseName": "Respiratory disease, unspecified",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D012120",
                    "name": "Respiration Disorders"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:519.9",
                    "name": "Unspecified disease of respiratory system"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "J98.9",
                    "name": "Respiratory disorder, unspecified"
                  },
                  {
                    "icd10Id": "P28.9",
                    "name": "Respiratory condition of newborn, unspecified"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED50043002",
                    "name": "Respiratory disorder"
                  }]
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-17T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-17T10:51:26.927Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Antiasthma",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Respiratory",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Gene expression inhibitor",
            "mechanismSynonyms": ["General transcription inhibitor", "Gene promoter inhibitor", "General translation inhibitor"],
            "mechanismHierarchy": "Gene expression inhibitor"
          },
          {
            "directMechanism": "Advanced glycosylation end product receptor antagonist",
            "mechanismSynonyms": ["RAGE antagonist", "AGER antagonist"],
            "mechanismHierarchy": "Immunoglobulin inhibitor:Advanced glycosylation end product receptor antagonist"
          }],
        "deliveryRoutes": ["Unspecified"],
        "drugSupportingUrls": ["https://arrowheadpharma.com/about/", "https://arrowheadpharma.com/pipeline/", "https://ir.arrowheadpharma.com/static-files/e9d35e6e-643d-4712-83da-ff51a434c077"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Chemical, synthetic, nucleic acid",
        "casNumbers": [],
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "USA",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "advanced glycosylation end-product specific receptor",
            "entrezGeneId": 177,
            "targetFamilies": ["Receptor > Cytokine receptor > Immunoglobulin family"],
            "targetECNumbers": [],
            "targetSynonyms": ["advanced glycosylation end product-specific receptor", "advanced glycosylation end product-specific receptor RAGE3", "advanced glycosylation end product-specific receptor variant sRAGE1", "advanced glycosylation end product-specific receptor variant sRAGE2", "AGER", "DAQB-143M3.1", "MGC22357", "RAGE", "RAGE isoform NtRAGE-delta", "RAGE isoform sRAGE-delta", "receptor for advanced glycosylation end-products"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "USA",
        "updatedDate": "2022-02-19T06:45:13.03Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210619",
        "drugId": 210619,
        "drugPrimaryName": "TPN7-29MA",
        "drugNameSynonyms": ["TPN 729", "TPN-729", "TPN7 29MA", "TPN7-29MA", "TPN729", "TPN729MA"],
        "overview": "TPN-729MA is an innovative PDE5 inhibitor under development by Tianfang Pharmaceutical for the treatment of erectile dysfunction (China Drug Trials, 17 Feb 2022, CTR20201917, http://www.chinadrugtrials.org.cn/index.html).",
        "marketing": "",
        "licensing": "",
        "phaseI": "A randomized, double-blind, placebo-controlled phase I study in 42 participants to evaluate the safety, tolerability and pharmacokinetics of TPN729MA tablets in healthy volunteers after single administration is complete (China Drug Trials, 17 Feb 2022, CTR20131391, http://www.chinadrugtrials.org.cn/index.html).\n\nA randomized, double-blind, placebo-controlled phase I study in 24 participants to evaluate the safety, tolerability and pharmacokinetics of multiple doses of TPN729MA tablets in healthy volunteers is complete (China Drug Trials, 17 Feb 2022, CTR20150560, http://www.chinadrugtrials.org.cn/index.html).",
        "phaseII": "A randomized, double-blind, placebo-controlled, dose-finding, multicenter, phase II clinical trial of TPN729MA tablets in 200 participants in the treatment of erectile dysfunction is complete (China Drug Trials, 17 Feb 2022, CTR20201917, http://www.chinadrugtrials.org.cn/index.html).",
        "phaseIII": "",
        "preClinical": "",
        "globalStatus": "Phase II Clinical Trial",
        "developmentStatus": "Active",
        "originatorName": "Tianfang Pharmaceutical",
        "originatorStatus": "Phase II Clinical Trial",
        "originatorCompanyKey": "17151",
        "originatorParentName": "China National Pharmaceutical",
        "originatorParentKey": "8449",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 8,
            "name": "Genitourinary (including sex hormones)",
            "indications": [
              {
                "diseaseName": "Impotence",
                "diseaseStatus": "Phase II Clinical Trial",
                "drugMeshTerms": [
                  {
                    "meshId": "D007172",
                    "name": "Erectile Dysfunction"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:607.84",
                    "name": "Impotence of organic origin"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "N52.9",
                    "name": "Male erectile dysfunction, unspecified"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED397803000",
                    "name": "Impotence"
                  }]
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-17T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Phase II Clinical Trial"
          }],
        "latestChangeDate": "2022-02-17T12:06:46.987Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Male sexual dysfunction",
            "therapeuticClassStatus": "Phase II Clinical Trial"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Phosphodiesterase 5 inhibitor",
            "mechanismSynonyms": ["PDE V inhibitor", "PDE 5 inhibitor", "cGMP-specific phosphodiesterase inhibitor", "Phosphodiesterase V inhibitor", "Phosphodiesterase cGMP-specific inhibitor"],
            "mechanismHierarchy": "Esterase inhibitor:Phosphodiesterase inhibitor:Phosphodiesterase 5 inhibitor"
          }],
        "deliveryRoutes": ["Oral"],
        "drugSupportingUrls": ["http://stock.jrj.com.cn/2018/07/31182324885841.shtml", "http://www.chinadrugtrials.org.cn/index.html", "https://med.sina.com/article_detail_100_1_50369.html"],
        "deliveryMediums": ["Tablet"],
        "deliveryTechnologies": [],
        "origin": "Chemical, synthetic",
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "China",
            "status": "Phase II Clinical Trial",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "phosphodiesterase 5A",
            "entrezGeneId": 8654,
            "targetFamilies": ["Enzyme > Esterase"],
            "targetECNumbers": ["Enzyme > EC number > 3.1.4.17"],
            "targetSynonyms": ["CGB-PDE", "cGMP-binding cGMP-specific 3',5'-cyclic nucleotide phosphodiesterase", "cGMP-specific 3',5'-cyclic phosphodiesterase", "cGMP-specific phosphodiesterase PDE5A2", "cGMP-specific phosphodiesterase type 5A", "CN5A", "PDE-V", "PDE5", "PDE5A", "PDE5A1", "phosphodiesterase 5A, cGMP-specific", "phosphodiesterase isozyme 5", "phosphodiesterase V"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "China",
        "updatedDate": "2022-02-18T11:10:42.367Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210621",
        "drugId": 210621,
        "drugPrimaryName": "MAX-8",
        "drugNameSynonyms": ["MAX 8", "MAX-8", "MAX8"],
        "overview": "MAX-8 is a radioligand therapy under development by Maxinovel Pharmaceuticals for the treatment of cancer (Company pipeline, Maxinovel, 17 Feb 2022, https://www.maxinovel.com/en/category/index/13.html).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is in preclinical development (Company pipeline, Maxinovel, 17 Feb 2022, https://www.maxinovel.com/en/category/index/13.html).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Maxinovel Pharmaceuticals",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "11932",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 12,
            "name": "Anticancer Products",
            "indications": [
              {
                "diseaseName": "Cancer, unspecified",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D009369",
                    "name": "Neoplasms"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:239",
                    "name": "Neoplasms of unspecified nature"
                  },
                  {
                    "icd9Id": "ICD9CM:338.3",
                    "name": "Neoplasm related pain (acute) (chronic)"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "C79.9",
                    "name": "Secondary malignant neoplasm of unspecified site"
                  },
                  {
                    "icd10Id": "C80.1",
                    "name": "Malignant (primary) neoplasm, unspecified"
                  },
                  {
                    "icd10Id": "D49.9",
                    "name": "Neoplasm of unspecified behavior of unspecified site"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED363346000",
                    "name": "Malignant tumour"
                  },
                  {
                    "snomedId": "SNOMED55342001",
                    "name": "Neoplastic disease"
                  }]
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-17T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-17T12:53:26.523Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Anticancer, other",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Radiopharmaceutical",
            "mechanismSynonyms": ["Radiocompound", "Medicinal radiocompound"],
            "mechanismHierarchy": "Radiopharmaceutical"
          }],
        "deliveryRoutes": ["Unspecified"],
        "drugSupportingUrls": ["https://www.maxinovel.com/en/category/index/13.html"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Chemical, synthetic",
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "China",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "China",
        "updatedDate": "2022-02-17T13:29:01.337Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210622",
        "drugId": 210622,
        "drugPrimaryName": "abiraterone acetate, Jiangsu Lianhuan Pharmaceutical Co",
        "drugNameSynonyms": ["abiraterone acetate, Jiangsu Lianhuan Pharmaceutical Co"],
        "globalStatus": "Clinical Trial",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Anticancer, hormonal",
            "therapeuticClassStatus": "Clinical Trial"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "17,20 lyase inhibitor",
            "mechanismSynonyms": ["17,20 desmolase inhibitor", "Steroid 17alpha-monooxygenase inhibitor", "CYP17A1 inhibitor", "17alpha hydroxylase inhibitor"],
            "mechanismHierarchy": "Lyase inhibitor:17,20 lyase inhibitor"
          },
          {
            "directMechanism": "Steroid synthesis inhibitor",
            "mechanismSynonyms": [],
            "mechanismHierarchy": "Steroid synthesis inhibitor"
          }],
        "deliveryRoutes": ["Oral"],
        "drugSupportingUrls": [],
        "deliveryMediums": ["Tablet"],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [420518],
        "isPharmaProjectsDrug": "False",
        "drugSource": "NonClinicalTrials.gov",
        "updatedDate": "2022-02-17T13:29:51.943Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210624",
        "drugId": 210624,
        "drugPrimaryName": "CTX-102",
        "drugNameSynonyms": ["CTX 102", "CTX-102", "CTX102"],
        "overview": "CTX-102 is a biological payload oncolytic virus and gene therapy, under development by Coastar Therapeutics for the treatment of breast cancer (Company pipeline, Coastar Therapeutics, 17 Feb 2022, https://coastartherapeutics.com/products/).",
        "marketing": "",
        "licensing": "Agreements\n________________\n\nJocavio\nWorldwide; Coastar Therapeutics has an exclusive worldwide license agreement with Jocavio (Company pipeline, Coastar Therapeutics, 17 Feb 2022, https://coastartherapeutics.com/products/).\n\nAvailability\n________________\n\nCoastar Therapeutics\nWorldwide; it is available for co-development of product (Company pipeline, Coastar Therapeutics, 17 Feb 2022, https://coastartherapeutics.com/products/).",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is at the discovery stage (Company pipeline, Coastar Therapeutics, 17 Feb 2022, https://coastartherapeutics.com/products/).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Coastar Therapeutics",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "19543",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 12,
            "name": "Anticancer",
            "indications": [
              {
                "diseaseName": "Cancer, lung, unspecified",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D008175",
                    "name": "Lung Neoplasms"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:162.9",
                    "name": "Malignant neoplasm of bronchus and lung, unspecified"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "C34.90",
                    "name": "Malignant neoplasm of unspecified part of unspecified bronchus or lung"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED363358000",
                    "name": "Malignant tumor of lung"
                  },
                  {
                    "snomedId": "SNOMED93880001",
                    "name": "Primary malignant neoplasm of lung"
                  }]
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-17T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          },
          {
            "keyEventDate": "2022-02-17T00:00:00Z",
            "keyEventHistory": "New Licensing Opportunity",
            "keyEventDetail": "Worldwide"
          }],
        "latestChangeDate": "2022-02-17T14:28:06.093Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Anticancer, immunological",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Gene therapy",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Lytic virus",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Immuno-oncology therapy",
            "mechanismSynonyms": ["Immune-oncology therapy", "Anticancer immunotherapy", "Anticancer immunomodulator", "IO"],
            "mechanismHierarchy": "Immuno-oncology therapy"
          }],
        "deliveryRoutes": ["Unspecified"],
        "drugSupportingUrls": ["https://coastartherapeutics.com/products/"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Biological, nucleic acid, viral vector",
        "casNumbers": [],
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "USA",
            "status": "Preclinical",
            "licensingOpportunity": "Y"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "USA",
        "updatedDate": "2022-02-18T13:18:06.803Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210626",
        "drugId": 210626,
        "drugPrimaryName": "5-MeO-DMT, Beckley Psytech",
        "drugNameSynonyms": ["5-MeO-DMT, Beckley Psytech"],
        "overview": "Beckley Psytech is developing a novel intranasal formulation of 5-MeO-DMT for treatment-resistant depression (Press release, Beckley Psytech, 15 Aug 2021, https://www.businesswire.com/news/home/20210815005009/en/Beckley-Psytech-completes-oversubscribed-80m-%C2%A358m-fundraise-to-develop-portfolio-of-psychedelic-medicine-breakthroughs; ClincialTrials.gov, 17 Feb 2022, https://clinicaltrials.gov/ct2/show/study/NCT05032833).",
        "marketing": "",
        "licensing": "",
        "phaseI": "It is in a double-blind, randomised, single ascending dose Phase I trial in the UK in 42 psychedelic-naïve healthy subjects, to evaluate the safety and tolerability of a novel formulation of intranasal 5-MeO-DMT (Press release. Beckley Psytech, 25 Oct 2021, https://www.beckleypsytech.com/our-news/post.php?post=beckley-psytech-announces-first-cohort-dosed-in-phase; ClinicalTrials.gov, 17 Feb 2022, https://clinicaltrials.gov/ct2/show/study/NCT05032833)",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "",
        "globalStatus": "Phase I Clinical Trial",
        "developmentStatus": "Active",
        "originatorName": "Beckley Psytech",
        "originatorStatus": "Phase I Clinical Trial",
        "originatorCompanyKey": "18147",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 14,
            "name": "Neurological",
            "indications": [
              {
                "diseaseName": "Depression, major depressive disorder",
                "diseaseStatus": "Phase I Clinical Trial",
                "drugMeshTerms": [
                  {
                    "meshId": "D003865",
                    "name": "Major Depressive Disorder"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:296.2",
                    "name": "Major depressive disorder, single episode"
                  },
                  {
                    "icd9Id": "ICD9CM:296.20",
                    "name": "Major depressive affective disorder, single episode, unspecified"
                  },
                  {
                    "icd9Id": "ICD9CM:296.3",
                    "name": "Major depressive disorder, recurrent episode"
                  },
                  {
                    "icd9Id": "ICD9CM:296.30",
                    "name": "Major depressive affective disorder, recurrent episode, unspecified"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "F32.9",
                    "name": "Major depressive disorder, single episode, unspecified"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED35489007",
                    "name": "Depressive disorder"
                  },
                  {
                    "snomedId": "SNOMED370143000",
                    "name": "Major depressive disorder"
                  }]
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-17T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Phase I Clinical Trial"
          }],
        "latestChangeDate": "2022-02-17T16:44:18.53Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Antidepressant",
            "therapeuticClassStatus": "Phase I Clinical Trial"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "5 Hydroxytryptamine 1A receptor agonist",
            "mechanismSynonyms": ["5-HT1A receptor agonist", "Serotonin 1A receptor agonist", "5HT1A receptor agonist"],
            "mechanismHierarchy": "5 Hydroxytryptamine receptor agonist:5 Hydroxytryptamine 1 receptor agonist:5 Hydroxytryptamine 1A receptor agonist"
          },
          {
            "directMechanism": "5 Hydroxytryptamine 2A receptor agonist",
            "mechanismSynonyms": ["5HT2A receptor agonist", "Serotonin 2A receptor agonist", "5-HT2A receptor agonist"],
            "mechanismHierarchy": "5 Hydroxytryptamine receptor agonist:5 Hydroxytryptamine 2 receptor agonist:5 Hydroxytryptamine 2A receptor agonist"
          }],
        "deliveryRoutes": ["Inhaled", "Inhaled, transnasal"],
        "drugSupportingUrls": ["https://clinicaltrials.gov/ct2/show/study/NCT05032833", "https://www.beckleypsytech.com/our-news/post.php?post=beckley-psytech-announces-first-cohort-dosed-in-phase", "https://www.businesswire.com/news/home/20210815005009/en/Beckley-Psytech-completes-oversubscribed-80m-%C2%A358m-fundraise-to-develop-portfolio-of-psychedelic-medicine-breakthroughs"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Chemical, synthetic",
        "casNumbers": [],
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "UK",
            "status": "Phase I Clinical Trial",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "5-hydroxytryptamine receptor 1A",
            "entrezGeneId": 3350,
            "targetFamilies": ["Receptor > GPCR > 5-Hydroxytryptamine"],
            "targetECNumbers": [],
            "targetSynonyms": ["5-hydroxytryptamine (serotonin) receptor 1A", "5-hydroxytryptamine (serotonin) receptor 1A, G-protein-coupled", "5-hydroxytryptamine receptor 1A", "5HT1a", "5HT1A receptor", "ADRB2RL1", "ADRBRL1", "beta-2-adrenergic receptor-like protein G-21", "G-21", "HTR1A", "PFMCD", "serotonin receptor 1A"]
          },
          {
            "targetName": "5-hydroxytryptamine receptor 2A",
            "entrezGeneId": 3356,
            "targetFamilies": ["Receptor > GPCR > 5-Hydroxytryptamine"],
            "targetECNumbers": [],
            "targetSynonyms": ["5-hydroxytryptamine (serotonin) receptor 2A", "5-hydroxytryptamine (serotonin) receptor 2A, G-protein-coupled", "5HT2A receptor", "HTR2", "HTR2A", "serotonin receptor 2A"]
          }],
        "trialIds": [412920],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "UK",
        "updatedDate": "2022-02-18T12:06:16.69Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210629",
        "drugId": 210629,
        "drugPrimaryName": "\"Envafolimab\" and \"Chemotherapy\" and \"Recombinant Human Endostatin\"",
        "drugNameSynonyms": ["\"Envafolimab\" and \"Chemotherapy\" and \"Recombinant Human Endostatin\""],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425394],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:31:34.13Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210630",
        "drugId": 210630,
        "drugPrimaryName": "[14C]-BLU-5937",
        "drugNameSynonyms": ["[14C]-BLU-5937"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425358],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:31:42.93Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210631",
        "drugId": 210631,
        "drugPrimaryName": "20 ml blood test",
        "drugNameSynonyms": ["20 ml blood test"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425393],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:31:50.227Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210632",
        "drugId": 210632,
        "drugPrimaryName": "89Zr-DFO-YS5",
        "drugNameSynonyms": ["89Zr-DFO-YS5"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425350],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:31:57.67Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210633",
        "drugId": 210633,
        "drugPrimaryName": "Afrezza (insulin human) Inhalation Powder",
        "drugNameSynonyms": ["Afrezza (insulin human) Inhalation Powder"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425387],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:32:05.397Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210634",
        "drugId": 210634,
        "drugPrimaryName": "anti-IL-17 antibody administration",
        "drugNameSynonyms": ["anti-IL-17 antibody administration"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425372],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:32:12.693Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210635",
        "drugId": 210635,
        "drugPrimaryName": "anti-TNF antibody administration",
        "drugNameSynonyms": ["anti-TNF antibody administration"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425372],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:32:20.257Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210636",
        "drugId": 210636,
        "drugPrimaryName": "BMS-986403",
        "drugNameSynonyms": ["BMS 986403", "BMS-986403", "BMS986403"],
        "overview": "BMS-986403 is under development by Bristol-Myers Squibb for the treatment of chronic lymphocytic leukaemia (R/R CLL) or small lymphocytic lymphoma (ClinicalTrials.gov, 17 Feb 2022, https://clinicaltrials.gov/ct2/show/NCT05244070).",
        "marketing": "",
        "licensing": "",
        "phaseI": "Cancer, leukaemia, chronic lymphocytic\nAn open-label, non-randomized Phase I trial (CA097-001; 2021-003274-31) in Canada, France, Italy, Spain, the UK and the US in 65 subjects with relapsed and/or refractory chronic lymphocytic leukaemia (R/R CLL) or small lymphocytic lymphoma, to evaluate the safety and preliminary efficacy of BMS-986403, is planned (ClinicalTrials.gov, 17 Feb 2022, https://clinicaltrials.gov/ct2/show/NCT05244070).",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Bristol-Myers Squibb",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "96",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 12,
            "name": "Anticancer",
            "indications": [
              {
                "diseaseName": "Cancer, leukaemia, chronic lymphocytic",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D015451",
                    "name": "Leukemia, Lymphocytic, Chronic, B-Cell"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:204.1",
                    "name": "Lymphoid leukemia, chronic"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "C91.10",
                    "name": "Chronic lymphocytic leukemia of B-cell type not having achieved remission"
                  },
                  {
                    "icd10Id": "C91.11",
                    "name": "Chronic lymphocytic leukemia of B-cell type in remission"
                  },
                  {
                    "icd10Id": "C91.32",
                    "name": "Prolymphocytic leukemia of B-cell type, in relapse"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED51092000",
                    "name": "Chronic lymphocytic leukemia"
                  }]
              }]
          },
          {
            "id": 24,
            "name": "Rare Diseases",
            "indications": [
              {
                "diseaseName": "Cancer, leukaemia, chronic lymphocytic",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D015451",
                    "name": "Leukemia, Lymphocytic, Chronic, B-Cell"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:204.1",
                    "name": "Lymphoid leukemia, chronic"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "C91.10",
                    "name": "Chronic lymphocytic leukemia of B-cell type not having achieved remission"
                  },
                  {
                    "icd10Id": "C91.11",
                    "name": "Chronic lymphocytic leukemia of B-cell type in remission"
                  },
                  {
                    "icd10Id": "C91.32",
                    "name": "Prolymphocytic leukemia of B-cell type, in relapse"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED51092000",
                    "name": "Chronic lymphocytic leukemia"
                  }]
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-18T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-18T15:19:38.243Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Anticancer, other",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Unidentified pharmacological activity",
            "mechanismSynonyms": [],
            "mechanismHierarchy": "Unidentified pharmacological activity"
          }],
        "deliveryRoutes": ["Unspecified"],
        "drugSupportingUrls": ["https://clinicaltrials.gov/ct2/show/NCT05244070"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Chemical, synthetic",
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "USA",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "USA",
        "updatedDate": "2022-02-18T15:19:38.387Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210637",
        "drugId": 210637,
        "drugPrimaryName": "cardamom",
        "drugNameSynonyms": ["cardamom"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425349],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:32:35.543Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210638",
        "drugId": 210638,
        "drugPrimaryName": "CKD-386(3)",
        "drugNameSynonyms": ["CKD-386(3)"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425346],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:32:43.03Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210639",
        "drugId": 210639,
        "drugPrimaryName": "Continue current regimen",
        "drugNameSynonyms": ["Continue current regimen"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425388],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:32:50.573Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210640",
        "drugId": 210640,
        "drugPrimaryName": "dexmedetomidine-ketamine-lidocaine (DKL)",
        "drugNameSynonyms": ["dexmedetomidine-ketamine-lidocaine (DKL)"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425377],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:32:58.343Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210641",
        "drugId": 210641,
        "drugPrimaryName": "dexmeditomidine and bupivacaine",
        "drugNameSynonyms": ["dexmeditomidine and bupivacaine"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425368],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:33:05.72Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210642",
        "drugId": 210642,
        "drugPrimaryName": "Diosmin/ Hesperidin",
        "drugNameSynonyms": ["Diosmin/ Hesperidin"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425382],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:33:13.367Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210643",
        "drugId": 210643,
        "drugPrimaryName": "Droperidol Injectable Product",
        "drugNameSynonyms": ["Droperidol Injectable Product"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425366],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:33:21.373Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210644",
        "drugId": 210644,
        "drugPrimaryName": "fennel",
        "drugNameSynonyms": ["fennel"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425349],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:33:28.847Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210645",
        "drugId": 210645,
        "drugPrimaryName": "Fentanyl/Hydromorphone",
        "drugNameSynonyms": ["Fentanyl/Hydromorphone"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425370],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:33:36.54Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210646",
        "drugId": 210646,
        "drugPrimaryName": "GSK3511294 (Depemokimab)",
        "drugNameSynonyms": ["GSK3511294 (Depemokimab)"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425384],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:33:43.857Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210647",
        "drugId": 210647,
        "drugPrimaryName": "Nab-paclitaxel 260 mg/m2",
        "drugNameSynonyms": ["Nab-paclitaxel 260 mg/m2"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425355],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:33:51.223Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210648",
        "drugId": 210648,
        "drugPrimaryName": "Non-Vagifem?? LDVE, Estradiol",
        "drugNameSynonyms": ["Non-Vagifem?? LDVE, Estradiol"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425379],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:33:58.797Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210649",
        "drugId": 210649,
        "drugPrimaryName": "Oral vitamin D3 tablets",
        "drugNameSynonyms": ["Oral vitamin D3 tablets"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425375],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:34:06.33Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210650",
        "drugId": 210650,
        "drugPrimaryName": "Paclitaxel 175mg/m2",
        "drugNameSynonyms": ["Paclitaxel 175mg/m2"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425355],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:34:14.93Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210651",
        "drugId": 210651,
        "drugPrimaryName": "Pegylated Interferon Alfa 2a",
        "drugNameSynonyms": ["Pegylated Interferon Alfa 2a"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425374],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:34:22.503Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210652",
        "drugId": 210652,
        "drugPrimaryName": "pemetrexed 500mg/m2",
        "drugNameSynonyms": ["pemetrexed 500mg/m2"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425355],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:34:29.59Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210653",
        "drugId": 210653,
        "drugPrimaryName": "Placebo of Hepalatide",
        "drugNameSynonyms": ["Placebo of Hepalatide"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425374],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:34:36.69Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210654",
        "drugId": 210654,
        "drugPrimaryName": "Propofol-remifentanil sedation",
        "drugNameSynonyms": ["Propofol-remifentanil sedation"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425363],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:34:43.99Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210655",
        "drugId": 210655,
        "drugPrimaryName": "SPH5030 tablets",
        "drugNameSynonyms": ["SPH5030 tablets"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425348],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:34:51.66Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210656",
        "drugId": 210656,
        "drugPrimaryName": "Switch to B/F/TAF",
        "drugNameSynonyms": ["Switch to B/F/TAF"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425388],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:34:58.963Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210657",
        "drugId": 210657,
        "drugPrimaryName": "Tinlarebant",
        "drugNameSynonyms": ["Tinlarebant"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425367],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:35:06.29Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210658",
        "drugId": 210658,
        "drugPrimaryName": "Tislelizumab 200 mg",
        "drugNameSynonyms": ["Tislelizumab 200 mg"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425355],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:35:14.057Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210659",
        "drugId": 210659,
        "drugPrimaryName": "Vagifem??",
        "drugNameSynonyms": ["Vagifem??"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425379],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:35:21.607Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210660",
        "drugId": 210660,
        "drugPrimaryName": "vitamin D tablets",
        "drugNameSynonyms": ["vitamin D tablets"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425375],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:35:29.02Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210661",
        "drugId": 210661,
        "drugPrimaryName": "YS5 antibody",
        "drugNameSynonyms": ["YS5 antibody"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425350],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-17T23:35:36.243Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210662",
        "drugId": 210662,
        "drugPrimaryName": "antiviral programme, Arrowhead Pharmaceuticals",
        "drugNameSynonyms": ["antiviral programme, Arrowhead Pharmaceuticals"],
        "overview": "Arrowhead Pharmaceuticals is developing a new program for an undisclosed viral infection (Transcript, Arrowhead Pharmaceuticals, 2 Feb 2022, Page 16, https://ir.arrowheadpharma.com/static-files/e9d35e6e-643d-4712-83da-ff51a434c077; Company web page, Arrowhead Pharmaceuticals, 18 Feb 2022, https://arrowheadpharma.com/about/).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "In vivo\nIn a mouse model of infection the current lead compound reduced viral gene expression in the lung by 90%, and prevented body weight loss (Transcript, Arrowhead Pharmaceuticals, 2 Feb 2022, Page 16 & 17, https://ir.arrowheadpharma.com/static-files/e9d35e6e-643d-4712-83da-ff51a434c077).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Arrowhead Pharmaceuticals",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "8103",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 11,
            "name": "Anti-infective Products",
            "indications": [
              {
                "diseaseName": "Infection, viral, unspecified",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D014777",
                    "name": "Virus Diseases"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:079.99",
                    "name": "Unspecified viral infection"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "B34.9",
                    "name": "Viral infection, unspecified"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED34014006",
                    "name": "Viral disease"
                  }]
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-18T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-18T02:03:58.857Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Antiviral, other",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "RNA interference",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Gene expression inhibitor",
            "mechanismSynonyms": ["General transcription inhibitor", "General translation inhibitor", "Gene promoter inhibitor"],
            "mechanismHierarchy": "Gene expression inhibitor"
          }],
        "deliveryRoutes": ["Unspecified"],
        "drugSupportingUrls": ["https://arrowheadpharma.com/about/", "https://ir.arrowheadpharma.com/static-files/e9d35e6e-643d-4712-83da-ff51a434c077"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Chemical, synthetic, nucleic acid",
        "casNumbers": [],
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "USA",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "USA",
        "updatedDate": "2022-02-18T02:06:09.227Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210663",
        "drugId": 210663,
        "drugPrimaryName": "raltegravir, IIHR",
        "drugNameSynonyms": ["raltegravir, IIHR"],
        "globalStatus": "Clinical Trial",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Antiviral, anti-HIV",
            "therapeuticClassStatus": "Clinical Trial"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "HIV integrase inhibitor",
            "mechanismSynonyms": ["Integrase HIV specific inhibitor"],
            "mechanismHierarchy": "Viral replication inhibitor:HIV integrase inhibitor"
          }],
        "deliveryRoutes": ["Oral", "Oral, swallowed"],
        "drugSupportingUrls": [],
        "deliveryMediums": ["Tablet"],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [],
        "isPharmaProjectsDrug": "False",
        "drugSource": "NonClinicalTrials.gov",
        "updatedDate": "2022-02-18T06:28:43.767Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210666",
        "drugId": 210666,
        "drugPrimaryName": "IAP-0971",
        "drugNameSynonyms": ["IAP 0971", "IAP-0971", "IAP0971"],
        "overview": "IAP-0971 is under development by Shenghe (China) Biopharma for the treatment of solid tumours (Center for Drug Evaluation, NMPA, CXSL2101428, 18 Feb 2022, https://www.cde.org.cn/main/xxgk/listpage/4b5255eb0a84820cef4ca3e8b6bbe20c).",
        "marketing": "",
        "licensing": "",
        "phaseI": "An IND has been approved by the NMPA for clinical trials (Center for Drug Evaluation, NMPA, CXSL2101428, 22 Nov 2021, https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d).",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Shenghe (China) Biopharma",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "18018",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 12,
            "name": "Anticancer Products",
            "indications": [
              {
                "diseaseName": "Cancer, solid, unspecified",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D009369",
                    "name": "Neoplasms"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:140-239.99",
                    "name": "NEOPLASMS"
                  },
                  {
                    "icd9Id": "ICD9CM:199",
                    "name": "Malignant neoplasm without specification of site"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "C80.1",
                    "name": "Malignant (primary) neoplasm, unspecified"
                  },
                  {
                    "icd10Id": "D49.9",
                    "name": "Neoplasm of unspecified behavior of unspecified site"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED363346000",
                    "name": "Malignant tumour"
                  },
                  {
                    "snomedId": "SNOMED55342001",
                    "name": "Neoplastic disease"
                  }]
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-18T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          },
          {
            "keyEventDate": "2021-11-22T00:00:00Z",
            "keyEventHistory": "IND Filing",
            "keyEventDetail": "China; Cancer, solid, unspecified"
          }],
        "latestChangeDate": "2022-02-18T08:01:27.42Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Anticancer, other",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Unidentified pharmacological activity",
            "mechanismSynonyms": [],
            "mechanismHierarchy": "Unidentified pharmacological activity"
          }],
        "deliveryRoutes": ["Injectable"],
        "drugSupportingUrls": ["https://www.cde.org.cn/main/xxgk/listpage/4b5255eb0a84820cef4ca3e8b6bbe20c", "https://www.cde.org.cn/main/xxgk/listpage/9f9c74c73e0f8f56a8bfbc646055026d"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Biological, other",
        "casNumbers": [],
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "China",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "China",
        "updatedDate": "2022-02-18T08:05:11.91Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210667",
        "drugId": 210667,
        "drugPrimaryName": "AT-20494",
        "drugNameSynonyms": ["AT 20494", "AT-20494", "AT20494"],
        "overview": "AT-20494 is an orally bioavailable small molecule that selectively inhibits activity of mTORC1 for the treatment of chronic diseases including autosomal dominant polycystic kidney diseases (Press release,  Anakuria Therapeutics, 2 Feb 2022, https://www.businesswire.com/news/home/20220202005093/en/Navitor-Pharmaceuticals-Announces-Janssen-Has-Acquired-Anakuria-Therapeutics-Inc).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Anakuria Therapeutics",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "19622",
        "originatorParentName": "Johnson & Johnson",
        "originatorParentKey": "316",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 8,
            "name": "Genitourinary (including sex hormones)",
            "indications": [
              {
                "diseaseName": "Polycystic kidney disease",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D007690",
                    "name": "Polycystic Kidney Diseases"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:753.12",
                    "name": "Polycystic kidney, unspecified type"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "Q61.2",
                    "name": "Polycystic kidney, adult type"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED82525005",
                    "name": "Congenital cystic kidney disease"
                  }]
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-18T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-18T10:26:53.933Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Urological",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "mTORC1 kinase inhibitor",
            "mechanismSynonyms": [],
            "mechanismHierarchy": "Protein kinase inhibitor:Serine/threonine kinase inhibitor:mTOR kinase inhibitor:mTORC1 kinase inhibitor"
          }],
        "deliveryRoutes": ["Unspecified"],
        "drugSupportingUrls": ["https://www.businesswire.com/news/home/20220202005093/en/Navitor-Pharmaceuticals-Announces-Janssen-Has-Acquired-Anakuria-Therapeutics-Inc"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Chemical, synthetic",
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "USA",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "mechanistic target of rapamycin kinase",
            "entrezGeneId": 2475,
            "targetFamilies": ["Enzyme > Kinase"],
            "targetECNumbers": [],
            "targetSynonyms": ["FK506 binding protein 12-rapamycin associated protein 1", "FK506 binding protein 12-rapamycin associated protein 2", "FKBP-rapamycin associated protein", "FKBP12-rapamycin complex-associated protein 1", "FLJ44809", "FRAP", "FRAP1", "FRAP2", "mammalian target of rapamycin", "mechanistic target of rapamycin (serine/threonine kinase)", "MTOR", "mTOR kinase", "RAFT1", "rapamycin target protein", "rapamycin-associated protein FRAP2", "RAPT1"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "USA",
        "updatedDate": "2022-02-18T10:26:54.043Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210668",
        "drugId": 210668,
        "drugPrimaryName": "ibuprofen granules, Reyoung Pharmaceutical Co.",
        "drugNameSynonyms": ["ibuprofen granules, Reyoung Pharmaceutical Co."],
        "globalStatus": "Clinical Trial",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Antiarthritic, other",
            "therapeuticClassStatus": "Clinical Trial"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Cyclooxygenase 1 inhibitor",
            "mechanismSynonyms": ["PHS1", "PCOX1", "COX-1 inhibitor"],
            "mechanismHierarchy": "Oxygenase inhibitor:Cyclooxygenase inhibitor:Cyclooxygenase 1 inhibitor"
          },
          {
            "directMechanism": "Cyclooxygenase 2 inhibitor",
            "mechanismSynonyms": ["COX-2 inhibitor"],
            "mechanismHierarchy": "Oxygenase inhibitor:Cyclooxygenase inhibitor:Cyclooxygenase 2 inhibitor"
          }],
        "deliveryRoutes": ["Oral, swallowed"],
        "drugSupportingUrls": [],
        "deliveryMediums": ["Granules"],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425454],
        "isPharmaProjectsDrug": "False",
        "drugSource": "NonClinicalTrials.gov",
        "updatedDate": "2022-02-18T12:03:38.707Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210669",
        "drugId": 210669,
        "drugPrimaryName": "ADI-006",
        "drugNameSynonyms": ["ADI 006", "ADI-006", "ADI006"],
        "overview": "ADI-006 is an allogeneic gamma delta CAR-T cell therapy, under development by Adicet Bio for solid tumours and haematological malignancies (Company pipeline, Adicet Bio, 18 Feb 2022, https://www.adicetbio.com/pipeline/).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is at the discovery stage (Company pipeline, Adicet Bio, 18 Feb 2022, https://www.adicetbio.com/pipeline/).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Adicet Bio",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "10749",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 12,
            "name": "Anticancer",
            "indications": [
              {
                "diseaseName": "Cancer, solid, unspecified",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D009369",
                    "name": "Neoplasms"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:140-239.99",
                    "name": "NEOPLASMS"
                  },
                  {
                    "icd9Id": "ICD9CM:199",
                    "name": "Malignant neoplasm without specification of site"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "C80.1",
                    "name": "Malignant (primary) neoplasm, unspecified"
                  },
                  {
                    "icd10Id": "D49.9",
                    "name": "Neoplasm of unspecified behavior of unspecified site"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED363346000",
                    "name": "Malignant tumour"
                  },
                  {
                    "snomedId": "SNOMED55342001",
                    "name": "Neoplastic disease"
                  }]
              },
              {
                "diseaseName": "Cancer, haematological, unspecified",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D019337",
                    "name": "Hematologic Neoplasms"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:29.9",
                    "name": "Unspecified diseases of blood and blood-forming organs"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "C96",
                    "name": "Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED129154003",
                    "name": "Hematologic neoplasm"
                  }]
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-18T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-18T13:23:50.087Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Anticancer, immunological",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Gene therapy",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Cellular therapy, chimaeric antigen receptor",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "T cell stimulant",
            "mechanismSynonyms": ["General T cells stimulant", "T cells general stimulant"],
            "mechanismHierarchy": "Lymphocyte stimulant:T cell stimulant"
          },
          {
            "directMechanism": "Immuno-oncology therapy",
            "mechanismSynonyms": ["IO", "Anticancer immunotherapy", "Immune-oncology therapy", "Anticancer immunomodulator"],
            "mechanismHierarchy": "Immuno-oncology therapy"
          }],
        "deliveryRoutes": ["Injectable", "Injectable, intravenous"],
        "drugSupportingUrls": ["https://www.adicetbio.com/pipeline/"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Biological, cellular, heterologous",
        "casNumbers": [],
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "USA",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "USA",
        "updatedDate": "2022-02-18T14:03:20.447Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210670",
        "drugId": 210670,
        "drugPrimaryName": "CTX-103, Coastar Therapeutics",
        "drugNameSynonyms": ["CTX 103, Coastar Therapeutics", "CTX-103, Coastar Therapeutics", "CTX103, Coastar Therapeutics"],
        "overview": "CTX-103 is a biological payload oncolytic virus and gene therapy, under development by Coastar Therapeutics for the treatment of breast cancer (Company pipeline, Coastar Therapeutics, 18 Feb 2022, https://coastartherapeutics.com/products/).",
        "marketing": "",
        "licensing": "Agreements\n________________\n\nJocavio\nWorldwide; Coastar Therapeutics has an exclusive worldwide license agreement with Jocavio (Company pipeline, Coastar Therapeutics, 18 Feb 2022, https://coastartherapeutics.com/products/).\n\nAvailability\n________________\n\nCoastar Therapeutics\nWorldwide; it is available for co-development of product (Company pipeline, Coastar Therapeutics, 18 Feb 2022, https://coastartherapeutics.com/products/).",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is at the discovery stage (Company pipeline, Coastar Therapeutics, 18 Feb 2022, https://coastartherapeutics.com/products/).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Coastar Therapeutics",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "19543",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 12,
            "name": "Anticancer",
            "indications": [
              {
                "diseaseName": "Cancer, colorectal",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D015179",
                    "name": "Colorectal Neoplasms"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:153.9",
                    "name": "Malignant neoplasm of colon, unspecified site"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "C18.2",
                    "name": "Malignant neoplasm of ascending colon"
                  },
                  {
                    "icd10Id": "C18.3",
                    "name": "Malignant neoplasm of hepatic flexure"
                  },
                  {
                    "icd10Id": "C18.4",
                    "name": "Malignant neoplasm of transverse colon"
                  },
                  {
                    "icd10Id": "C18.5",
                    "name": "Malignant neoplasm of splenic flexure"
                  },
                  {
                    "icd10Id": "C18.6",
                    "name": "Malignant neoplasm of descending colon"
                  },
                  {
                    "icd10Id": "C18.7",
                    "name": "Malignant neoplasm of sigmoid colon"
                  },
                  {
                    "icd10Id": "C18.9",
                    "name": "Malignant neoplasm of colon, unspecified"
                  },
                  {
                    "icd10Id": "C19",
                    "name": "Malignant neoplasm of rectosigmoid junction"
                  },
                  {
                    "icd10Id": "C20",
                    "name": "Malignant neoplasm of rectum"
                  },
                  {
                    "icd10Id": "D49.0",
                    "name": "Neoplasm of unspecified behavior of digestive system"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED126838000",
                    "name": "Neoplasm of colon"
                  },
                  {
                    "snomedId": "SNOMED254582000",
                    "name": "Adenocarcinoma of rectum"
                  },
                  {
                    "snomedId": "SNOMED269533000",
                    "name": "Carcinoma of colon"
                  }]
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-18T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          },
          {
            "keyEventDate": "2022-02-18T00:00:00Z",
            "keyEventHistory": "New Licensing Opportunity",
            "keyEventDetail": "Worldwide"
          }],
        "latestChangeDate": "2022-02-18T13:31:38.02Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Anticancer, immunological",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Gene therapy",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Lytic virus",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Immuno-oncology therapy",
            "mechanismSynonyms": ["Anticancer immunotherapy", "Immune-oncology therapy", "IO", "Anticancer immunomodulator"],
            "mechanismHierarchy": "Immuno-oncology therapy"
          }],
        "deliveryRoutes": ["Unspecified"],
        "drugSupportingUrls": ["https://coastartherapeutics.com/products/"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Biological, nucleic acid, viral vector",
        "casNumbers": [],
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "USA",
            "status": "Preclinical",
            "licensingOpportunity": "Y"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "USA",
        "updatedDate": "2022-02-18T13:38:03.453Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210671",
        "drugId": 210671,
        "drugPrimaryName": "ADI-007",
        "drugNameSynonyms": ["ADI 007", "ADI-007", "ADI007"],
        "overview": "ADI-007 is an allogeneic gamma delta CAR-T cell therapy, under development by Adicet Bio for solid tumours and haematological malignancies (Company pipeline, Adicet Bio, 18 Feb 2022, https://www.adicetbio.com/pipeline/).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is at the discovery stage (Company pipeline, Adicet Bio, 18 Feb 2022, https://www.adicetbio.com/pipeline/).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Adicet Bio",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "10749",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 12,
            "name": "Anticancer",
            "indications": [
              {
                "diseaseName": "Cancer, solid, unspecified",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D009369",
                    "name": "Neoplasms"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:140-239.99",
                    "name": "NEOPLASMS"
                  },
                  {
                    "icd9Id": "ICD9CM:199",
                    "name": "Malignant neoplasm without specification of site"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "C80.1",
                    "name": "Malignant (primary) neoplasm, unspecified"
                  },
                  {
                    "icd10Id": "D49.9",
                    "name": "Neoplasm of unspecified behavior of unspecified site"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED363346000",
                    "name": "Malignant tumour"
                  },
                  {
                    "snomedId": "SNOMED55342001",
                    "name": "Neoplastic disease"
                  }]
              },
              {
                "diseaseName": "Cancer, haematological, unspecified",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D019337",
                    "name": "Hematologic Neoplasms"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:29.9",
                    "name": "Unspecified diseases of blood and blood-forming organs"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "C96",
                    "name": "Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED129154003",
                    "name": "Hematologic neoplasm"
                  }]
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-18T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-18T13:40:59.787Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Anticancer, immunological",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Gene therapy",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Cellular therapy, chimaeric antigen receptor",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "T cell stimulant",
            "mechanismSynonyms": ["General T cells stimulant", "T cells general stimulant"],
            "mechanismHierarchy": "Lymphocyte stimulant:T cell stimulant"
          },
          {
            "directMechanism": "Immuno-oncology therapy",
            "mechanismSynonyms": ["Anticancer immunotherapy", "Anticancer immunomodulator", "Immune-oncology therapy", "IO"],
            "mechanismHierarchy": "Immuno-oncology therapy"
          }],
        "deliveryRoutes": ["Injectable", "Injectable, intravenous"],
        "drugSupportingUrls": ["https://www.adicetbio.com/pipeline/"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Biological, cellular, heterologous",
        "casNumbers": [],
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "USA",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "USA",
        "updatedDate": "2022-02-18T13:58:07.427Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210672",
        "drugId": 210672,
        "drugPrimaryName": "ADI-008",
        "drugNameSynonyms": ["ADI 008", "ADI-008", "ADI008"],
        "overview": "ADI-008 is an allogeneic gamma delta CAR-T cell therapy, under development by Adicet Bio for solid tumours and haematological malignancies (Company pipeline, Adicet Bio, 18 Feb 2022, https://www.adicetbio.com/pipeline/).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is at the discovery stage (Company pipeline, Adicet Bio, 18 Feb 2022, https://www.adicetbio.com/pipeline/).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Adicet Bio",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "10749",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 12,
            "name": "Anticancer",
            "indications": [
              {
                "diseaseName": "Cancer, solid, unspecified",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D009369",
                    "name": "Neoplasms"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:140-239.99",
                    "name": "NEOPLASMS"
                  },
                  {
                    "icd9Id": "ICD9CM:199",
                    "name": "Malignant neoplasm without specification of site"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "C80.1",
                    "name": "Malignant (primary) neoplasm, unspecified"
                  },
                  {
                    "icd10Id": "D49.9",
                    "name": "Neoplasm of unspecified behavior of unspecified site"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED363346000",
                    "name": "Malignant tumour"
                  },
                  {
                    "snomedId": "SNOMED55342001",
                    "name": "Neoplastic disease"
                  }]
              },
              {
                "diseaseName": "Cancer, haematological, unspecified",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D019337",
                    "name": "Hematologic Neoplasms"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:29.9",
                    "name": "Unspecified diseases of blood and blood-forming organs"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "C96",
                    "name": "Other and unspecified malignant neoplasms of lymphoid, hematopoietic and related tissue"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED129154003",
                    "name": "Hematologic neoplasm"
                  }]
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-18T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-18T14:03:03.557Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Anticancer, immunological",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Gene therapy",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Cellular therapy, chimaeric antigen receptor",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "T cell stimulant",
            "mechanismSynonyms": ["T cells general stimulant", "General T cells stimulant"],
            "mechanismHierarchy": "Lymphocyte stimulant:T cell stimulant"
          },
          {
            "directMechanism": "Immuno-oncology therapy",
            "mechanismSynonyms": ["IO", "Anticancer immunomodulator", "Anticancer immunotherapy", "Immune-oncology therapy"],
            "mechanismHierarchy": "Immuno-oncology therapy"
          }],
        "deliveryRoutes": ["Injectable", "Injectable, intravenous"],
        "drugSupportingUrls": ["https://www.adicetbio.com/pipeline/"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Biological, cellular, heterologous",
        "casNumbers": [],
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "USA",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "USA",
        "updatedDate": "2022-02-18T14:07:59.18Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210673",
        "drugId": 210673,
        "drugPrimaryName": "beraprost sodium, YaoPharma Co.",
        "drugNameSynonyms": ["beraprost sodium, YaoPharma Co.", "beraprost, YaoPharma Co."],
        "globalStatus": "Clinical Trial",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Antithrombotic, other",
            "therapeuticClassStatus": "Clinical Trial"
          },
          {
            "therapeuticClassName": "Antihypertensive, other",
            "therapeuticClassStatus": "Clinical Trial"
          },
          {
            "therapeuticClassName": "Vasodilator, peripheral",
            "therapeuticClassStatus": "Clinical Trial"
          },
          {
            "therapeuticClassName": "Prostaglandin",
            "therapeuticClassStatus": "Clinical Trial"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Platelet aggregation inhibitor",
            "mechanismSynonyms": ["Platelet adhesion antagonist", "Antiplatelet"],
            "mechanismHierarchy": "Platelet aggregation inhibitor"
          },
          {
            "directMechanism": "Prostaglandin IP2 receptor agonist",
            "mechanismSynonyms": ["Prostaglandin I2 agonist", "PGI2 agonist", "Epoprostenol agonist"],
            "mechanismHierarchy": "Prostaglandin receptor agonist:Prostaglandin IP receptor agonist:Prostaglandin IP2 receptor agonist"
          }],
        "deliveryRoutes": ["Oral", "Oral, swallowed"],
        "drugSupportingUrls": [],
        "deliveryMediums": ["Tablet"],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425212],
        "isPharmaProjectsDrug": "False",
        "drugSource": "NonClinicalTrials.gov",
        "updatedDate": "2022-02-18T14:33:20.977Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210674",
        "drugId": 210674,
        "drugPrimaryName": "valsartan + hydrochlorothiazide, Canonpharma",
        "drugNameSynonyms": ["hydrochlorothiazide + valsartan, Canonpharma", "hydrochlorothiazide/valsartan, Canonpharma", "valsartan + hydrochlorothiazide, Canonpharma", "valsartan/ hydrochlorothiazide, Canonpharma"],
        "globalStatus": "Clinical Trial",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Cardiostimulant",
            "therapeuticClassStatus": "Clinical Trial"
          },
          {
            "therapeuticClassName": "Antihypertensive, renin system",
            "therapeuticClassStatus": "Clinical Trial"
          },
          {
            "therapeuticClassName": "Antihypertensive, diuretic",
            "therapeuticClassStatus": "Clinical Trial"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Angiotensin II 1 antagonist",
            "mechanismSynonyms": ["Angiotonin II 1 antagonist", "Hypertensin II AT1 antagonist", "Angiotensin II AT1 antagonist", "Hypertensin II 1 antagonist"],
            "mechanismHierarchy": "Angiotensin antagonist:Angiotensin II antagonist:Angiotensin II 1 antagonist"
          },
          {
            "directMechanism": "Thiazide diuretic",
            "mechanismSynonyms": ["Thiazide-like diuretic", "Diuretic electrolyte absorption type e.g. thiazides"],
            "mechanismHierarchy": "Diuretic:Thiazide diuretic"
          }],
        "deliveryRoutes": ["Oral", "Oral, swallowed"],
        "drugSupportingUrls": [],
        "deliveryMediums": ["Tablet"],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [],
        "isPharmaProjectsDrug": "False",
        "drugSource": "NonClinicalTrials.gov",
        "updatedDate": "2022-02-18T15:02:41.783Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210675",
        "drugId": 210675,
        "drugPrimaryName": "therapeutic antibodies, Channel Biologics",
        "drugNameSynonyms": ["therapeutic antibodies, Channel Biologics"],
        "overview": "Channel Biologics is developing therapeutic antibodies targeting GPCRs (G protein coupled receptors) and ion channels for the treatment of undisclosed diseases (Company Web Page, Channel Biologics, 18 Feb 2022, https://channelbio.com.au/#technology).",
        "marketing": "",
        "licensing": "",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "They are in preclinical development (Company Web Page, Channel Biologics, 18 Feb 2022, https://channelbio.com.au/#technology).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Channel Biologics",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "19638",
        "originatorParentName": "AbCellera Biologics",
        "originatorParentKey": "10731",
        "licensee": [],
        "indicationGroups": [
          {
            "id": 20,
            "name": "NA/Unspecified",
            "indications": [
              {
                "diseaseName": "Undisclosed",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [],
                "drugIcd9": [],
                "drugIcd10": [],
                "drugSnomed": []
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-18T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-18T18:36:44.783Z",
        "latestChange": "New product entry",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Monoclonal antibody, other",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Ion channel antagonist",
            "mechanismSynonyms": ["Unspecified ion channel blocker"],
            "mechanismHierarchy": "Ion channel antagonist"
          }],
        "deliveryRoutes": ["Injectable"],
        "drugSupportingUrls": ["https://channelbio.com.au/#technology"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Biological, protein, antibody",
        "casNumbers": [],
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "Australia",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "Australia",
        "updatedDate": "2022-02-21T09:30:31.55Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210676",
        "drugId": 210676,
        "drugPrimaryName": "haemophilia B gene therapy, Intellia Therapeutics",
        "drugNameSynonyms": ["haemophilia B gene therapy, Intellia Therapeutics", "haemophilia B gene therapy, Regeneron"],
        "overview": "Intellia Therapeutics in collaboration with Regeneron is developing an in-vivo gene therapy, using its CRISPR-Cas9 technology for haemophilia B (Company pipeline, Intellia Therapeutics, 19 Feb 2022, https://www.intelliatx.com/pipeline/; Company Web Page, Intellia Therapeutics, 19 Feb 2022, https://www.intelliatx.com/full-spectrum-approach/).",
        "marketing": "",
        "licensing": "Agreements\n________________\n\nRegeneron\nWorldwide; Intellia Therapeutics has expanded its licensing and collaboration agreement with Regeneron to advance CRISPR/Cas gene-editing technology for in vivo therapeutic development and to jointly develop potential products for the treatment of haemophilia A and B. Regeneron also receives non-exclusive rights to independently develop and commercialize ex vivo gene-edited products. Under the amended agreement, the term of the companies existing collaboration has been extended until April 2024, with Regeneron having an option to renew for an additional 2 yrs. Regeneron will have the rights to discover and develop CRISPR/Cas9-based therapeutic products for an additional five in vivo liver targets, for a total of up to 15 targets (Press release, Regeneron Pharmaceuticals, 1 Jun 2020, https://investor.regeneron.com/news-releases/news-release-details/regeneron-and-intellia-therapeutics-expand-collaboration-develop).",
        "phaseI": "",
        "phaseII": "",
        "phaseIII": "",
        "preClinical": "It is in IND-enabling studies for haemophilia B (Company presentation, Intellia Therapeutics, 6 Jan 2022, Slide 11, https://ir.intelliatx.com/static-files/a57908a6-aaca-404d-9072-32471cd3d41e).",
        "globalStatus": "Preclinical",
        "developmentStatus": "Active",
        "originatorName": "Intellia Therapeutics",
        "originatorStatus": "Preclinical",
        "originatorCompanyKey": "9325",
        "licensee": [
          {
            "licenseeName": "Regeneron",
            "licenseeStatus": "Preclinical",
            "licenseeCompanyKey": 742,
            "licenseeCountry": "USA"
          }],
        "indicationGroups": [
          {
            "id": 4,
            "name": "Blood and Clotting",
            "indications": [
              {
                "diseaseName": "Haemophilia B",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D002836",
                    "name": "Hemophilia B"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:286.1",
                    "name": "Congenital factor IX disorder"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "D67",
                    "name": "Hereditary factor IX deficiency"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED41788008",
                    "name": "Hemophilia B"
                  }]
              }]
          },
          {
            "id": 24,
            "name": "Rare Diseases",
            "indications": [
              {
                "diseaseName": "Haemophilia B",
                "diseaseStatus": "Preclinical",
                "drugMeshTerms": [
                  {
                    "meshId": "D002836",
                    "name": "Hemophilia B"
                  }],
                "drugIcd9": [
                  {
                    "icd9Id": "ICD9CM:286.1",
                    "name": "Congenital factor IX disorder"
                  }],
                "drugIcd10": [
                  {
                    "icd10Id": "D67",
                    "name": "Hereditary factor IX deficiency"
                  }],
                "drugSnomed": [
                  {
                    "snomedId": "SNOMED41788008",
                    "name": "Hemophilia B"
                  }]
              }]
          }],
        "bmtDrug": [],
        "keyEvents": [
          {
            "keyEventDate": "2022-02-19T00:00:00Z",
            "keyEventHistory": "Drug Added",
            "keyEventDetail": "Preclinical"
          }],
        "latestChangeDate": "2022-02-20T16:48:58.39Z",
        "latestChange": "Ongoing IND-enabling studies for haemophilia B reported",
        "therapeuticClasses": [
          {
            "therapeuticClassName": "Haemostatic",
            "therapeuticClassStatus": "Preclinical"
          },
          {
            "therapeuticClassName": "Gene therapy",
            "therapeuticClassStatus": "Preclinical"
          }],
        "mechanismsOfAction": [
          {
            "directMechanism": "Genome editing",
            "mechanismSynonyms": ["Gene editing"],
            "mechanismHierarchy": "Genome editing"
          }],
        "deliveryRoutes": ["Injectable"],
        "drugSupportingUrls": ["https://ir.intelliatx.com/static-files/a57908a6-aaca-404d-9072-32471cd3d41e", "https://www.intelliatx.com/full-spectrum-approach/", "https://www.intelliatx.com/pipeline/"],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "origin": "Biological, nucleic acid",
        "casNumbers": [],
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [
          {
            "name": "USA",
            "status": "Preclinical",
            "licensingOpportunity": "U"
          }],
        "patents": [],
        "targets": [
          {
            "targetName": "Unspecified",
            "targetFamilies": [],
            "targetECNumbers": [],
            "targetSynonyms": ["Unspecified"]
          }],
        "trialIds": [],
        "isPharmaProjectsDrug": "True",
        "drugSource": "NonClinicalTrials.gov",
        "originatorCountry": "USA",
        "updatedDate": "2022-02-20T16:48:58.47Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210677",
        "drugId": 210677,
        "drugPrimaryName": "[14C]M6620",
        "drugNameSynonyms": ["[14C]M6620"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425506],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-18T23:31:49.91Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210678",
        "drugId": 210678,
        "drugPrimaryName": "Biological Sample collection",
        "drugNameSynonyms": ["Biological Sample collection"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425493],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-18T23:31:58.413Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210679",
        "drugId": 210679,
        "drugPrimaryName": "convalescent plasma infusion covid 19",
        "drugNameSynonyms": ["convalescent plasma infusion covid 19"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425482],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-18T23:32:06.37Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210680",
        "drugId": 210680,
        "drugPrimaryName": "Conventional general anesthesia by administration of sevoflurane alone",
        "drugNameSynonyms": ["Conventional general anesthesia by administration of sevoflurane alone"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425487],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-18T23:32:13.95Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210681",
        "drugId": 210681,
        "drugPrimaryName": "Copper Cu 64 Anti-CEA Monoclonal Antibody M5A",
        "drugNameSynonyms": ["Copper Cu 64 Anti-CEA Monoclonal Antibody M5A"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425516],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-18T23:32:21.71Z"
      },
      {
        "$type": "Pharma.Api.Schema.Drug.Drug, Pharma.Api.Schema",
        "copyrightNotice": "Data from Pharmaprojects pipeline drug development monitoring database. Copyright Citeline, Inc. 2022.",
        "recordUrl": "https://citeline.informa.com/#/drugs/details/210682",
        "drugId": 210682,
        "drugPrimaryName": "COVID-19 Vaccine 40 ug/dose",
        "drugNameSynonyms": ["COVID-19 Vaccine 40 ug/dose"],
        "globalStatus": "Not Applicable",
        "developmentStatus": "Active",
        "licensee": [],
        "indicationGroups": [],
        "bmtDrug": [],
        "keyEvents": [],
        "therapeuticClasses": [],
        "mechanismsOfAction": [],
        "deliveryRoutes": [],
        "drugSupportingUrls": [],
        "deliveryMediums": [],
        "deliveryTechnologies": [],
        "casNumbers": [],
        "nce": 1,
        "chemicalStructure": [],
        "chemicalData": [],
        "pharmacokinetics": [],
        "drugCountries": [],
        "patents": [],
        "targets": [],
        "trialIds": [425505],
        "isPharmaProjectsDrug": "False",
        "drugSource": "ClinicalTrials.gov",
        "updatedDate": "2022-02-18T23:32:29.463Z"
      }
    ]
  },
  getters: {
    drugs({ state }) {
      return state.drugs;
    }
  },
  actions: {
    addProduct({ state }, product) {
      state.drugs = [...state.drugs, product];
    },
  },
})

